

業績目録(山添康)

著者	東北大学史料館
雑誌名	東北大学定年退職教員業績目録
号	2012-21
発行年	2013-03
URL	http://hdl.handle.net/10097/56603

東北大学定年退職教員業績目録第 2012-21 号

山 添 康 名誉教授 業績目録

平成25年3月
東北大学史料館

山添 康

YAMAZOE Yasushi

最終所属部局	薬学研究科	専攻
職名	教授	
生年月日	1949年2月8日生	
出身大学	大阪大学薬学部製薬化学科	1971年卒業
出身大学院	大阪大学大学院薬学研究科修士課程	1973年修了
取得学位	薬学博士(大阪大学)	1981年
略歴	藤沢薬品工業入社中央研究所勤務 慶應義塾大学助手(医学部薬理学) 米国FDA, National Center For Toxicological Research Visiting scientist, (Fred F. Kadlubar_発がん研究部門) 1983-5年 慶應義塾大学専任講師(医学部薬理学) 1986年 慶應義塾大学助教授_(医学部薬理学) 1990年 東北大学教授(薬学部衛生化学) 1994年 東北大学大学院薬学研究科教授・薬物動態学 2001-2012年 内閣府食品安全委員会 委員 2012-現在	

「研究活動に関する情報」

専門分野

1. 薬物代謝・動態
2. 生化学薬理
3. 毒性学

所属学会

日本薬学会、日本癌学会、日本薬理学会、日本環境変異原学会、日本毒性学会、
日本薬物動態会、日本内分泌学会、日本生化学会、

International Society For Study of Xenobiotics

学会活動

日本薬学会_(監事、元理事),
日本癌学会_(Assoc. Ed.),
日本環境変異原学会(元会長),

日本トキシコロジー学会（現日本毒性学会 元理事長），

日本薬物動態会（元会長）

International Society for the Study of Xenobiotics（Ex Councillor）

学術誌編集

Pharmacogenetics (Ex. Editor, Editorial Board),

Drug Metabolism Review (Associate Editor)

Mutation Research (Ex. Editorial Board),

Drug Metabolism and Disposition (Ex. Editorial Board),

Cancer Letters (EX. Editorial Board),

Xenobiotica (Editorial Board).

学術受賞

慶應義塾大学医学部三四会奨励賞	昭和60年6月_
日本癌学会奨励賞	昭和62年9月
日本環境変異原学会奨励賞	昭和63年10月_
望月喜多司記念賞奨励賞(毒科学)	平成元年3月_
日本薬物動態学会奨励賞	平成_2年10月_
慶應義塾大学医学部三四会北里賞	平成_3年6月
日本薬学会奨励賞	平成_4年3月
日本薬物動態学会学会賞	平成13年10月_
望月喜多司記念賞学術賞	平成16年3月
日本環境変異原学会学会賞	平成24年11月
日本毒性学会学会賞	平成25年6月(予定)

「社会活動に関する情報」

文部省大学設置審議会専門委員	1998-2000(平成10-12年)
厚生労働省薬事・食品審議会委員	1998-2010(平成10-22年)
厚生労働省薬剤師試験委員	2000-2005(平成12-17年)
内閣府食品安全委員会専門委員	2003-2012(平成15-24年)
大学評価・学位授与機構専門委員	2002-2012(平成14-24年)
消費者庁審議会専門委員	2008-2012(平成20-24年)
日本学術会議連携会員	2006-

I 編著

1. Heterocyclic amines in cooked foods: Possible human carcinogens: Adamson, R. H., Gustafsson, J-Å, Ito, N., Nagao, M., Sugimura, T., Wakabayashi, K., Yamazoe, Y. 1995 Princeton Scientific Publishing
2. 衛生薬学新論: 井上圭三, 小栗一太, 山添康 2001 南山堂
薬物動態研究ガイド: 佐藤哲男, 堀井邦雄, 山添康 2003 エル・アイ・シー
3. 摘出ヒト組織・細胞を用いた非臨床研究: 大野泰雄, 上川雄一郎, 杉山雄一, 山添康 2005 エル・アイ・シー
4. 薬物代謝学 医療薬学・医薬品開発の基礎として: 加藤隆一, 山添康, 横井毅 2010 東京化学同人

II 論文等

(1) 英文

- 1 Kitagawa, I., Yamazoe, Y., Takeda, R., Yoshioka, I. (1972). Conversion of dihydroalantolactone to eremophilane-type derivatives: A biogenetic-type transformation. *Tetrahedron Lett* 1972:4843-4846.
- 2 Kitagawa, I., Shibuya, H., Yamazoe, Y., Takeno, H., Yoshioka, I. (1974a). Conversion of dihydroalantolactone to tetrahydro-
ligularenolide, a biogenic-type transformation of eudesmanolide to eremophilanoide. *Tetrahedron Lett* 1974:111-114.
- 3 Kitagawa, I., Yamazoe, Y., Shibuya, H., Takeda, R., Yoshioka, I. (1974b). Biogenetically patterned transformation of eudesmanolide to eremophilanolide. 1. Angular methyl migration of 5α , 6α -epoxy-
dihydroalantolactone. *Chem Pharm Bull* 22:2662-2674.
- 4 Yamazoe, Y., Sugiura, M., Kamataki, T., Kato, R. (1978). Reconstitution of benzo[a]pyrene 4,5-oxide reductase activity by purified cytochrome P-450. *FEBS Lett* 88:337-340.
- 5 Kamataki, T., Sugiura, M., Yamazoe, Y., Kato, R. (1979). Purification and properties of cytochrome P-450 and NADPH-cytochrome *c* (P-450) reductase from human liver microsomes. *Biochem Pharmacol* 28:1993-2000.
- 6 Yamazoe, Y., Sugiura, M., Kamataki, T., Kato, R. (1979). The apparent loss of cytochrome P-450 associated with metabolic activation of carbon

- tetrachloride. Japan J Pharmacol 29:715-721.
- 7 Ishii, K., Yamazoe, Y., Kamataki, T., Kato, R. (1980). Metabolic activation of mutagenic tryptophan pyrolysis products by rat liver microsomes. Cancer Res 40:2596-2600.
- 8 Kamataki, T., Ando, M., Yamazoe, Y., Ishii, K., Kato, R. (1980a). Sex difference in the *O*-dealkylation activity of 7-hydroxycoumarin *O*-alkyl derivatives in liver microsomes of rats. Biochem Pharmacol 29:1015-1022.
- 9 Kamataki, T., Ando, M., Yamazoe, Y., Ishii, K., Kato, R. 1980b. Studies on sex differences in the *O*-dealkylation activities of 7-hydroxycoumarin *O*-alkyl derivatives in liver microsomes of rats. In: Coon MJ, Conney AH, Estabrook RW, Gelboin HV, Gillette JR, O'Brien PJ, editors. Microsomes, Drug, Oxidations and Chemical Carcinogenesis. New York: Academic Press. p 965-968.
- 10 Kato, R., Yamazoe, Y., Kamataki, T. 1980. Metabolic activation of tryptophan pyrolysates, Trp-P-1 and Trp-P-2 by hepatic cytochrome P-450. In: Gelboin HV, MacMahon B, Matsushima T, Sugimura T, Takayama S, Takebe H, editors. Genetic and Environmental Factors in Experimental and Human Cancer. Tokyo: Japan Sci. Soc. Press. p 79-87.
- 11 Sugiura, M., Yamazoe, Y., Kamataki, T., Kato, R. (1980). Reduction of epoxy derivatives of benzo(a)pyrene by microsomal cytochrome P-450. Cancer Res 40:2910-2914.
- 12 Yamazoe, Y., Ishii, K., Kamataki, T., Kato, R., Sugimura, T. (1980a). Isolation and characterization of active metabolites of tryptophan-pyrolysate mutagen, Trp-P-2, formed by rat liver microsomes. Chem Biol Interact 30:125-138.
- 13 Yamazoe, Y., Ishii, K., Yamaguchi, N., Kamataki, T., Kato, R. (1980b). Reduction of *N*-hydroxy-2-acetylaminofluorene by liver microsomes. Biochem Pharmacol 29:2183-2188.
- 14 Yamazoe, Y., Yamaguchi, N., Kamataki, T., Kato, R. (1980c). Metabolic activation of Trp-P-2, a mutagenic amine from tryptophan-pyrolysate, by liver microsomes from 3-methylcholanthrene-responsive and non-responsive mice. Xenobiotica 10:483-494.
- 15 Ishii, K., Yamazoe, Y., Kamataki, T., Kato, R. (1981). Metabolic activation of

- glutamic acid pyrolysis products, 2-amino-6-methyldipyrido[1,2-*a*:3',2'-*d*]imidazole and 2-aminodipyrido[1,2-*a*:3',2'-*d*]imidazole, by purified cytochrome P-450. *Chem Biol Interact* 38:1-13.
- 16 Kamataki, T., Maeda, K., Yamazoe, Y., Nagai, T., Kato, R. (1981). Partial purification and characterization of cytochrome P-450 responsible for the occurrence of sex difference in drug metabolism in the rat. *Biochem Biophys Res Commun* 103:1-7.
- 17 Mita, S., Ishii, K., Yamazoe, Y., Kamataki, T., Kato, R., Sugimura, T. (1981a). Evidence for the involvement of *N*-hydroxylation of 3-amino-1-methyl-5*H*-pyrido[4,3-*b*]indole by cytochrome P-450 in the covalent binding to DNA. *Cancer Res* 41:3610-3614.
- 18 Mita, S., Yamazoe, Y., Kamataki, T., Kato, R. (1981b). Metabolic activation of a tryptophan pyrolysis product, 3-amino-1-methyl-5*H*-pyrido[4,3-*b*]indole (Trp-P-2) by isolated rat liver nuclei. *Cancer Lett* 14:261-266.
- 19 Yamazoe, Y., Ishii, K., Kamataki, T., Kato, R. (1981a). Structural elucidation of a mutagenic metabolite of 3-amino-1-methyl-5*H*-pyrido[4,3-*b*]indole. *Drug Metab Dispos* 9:292-296.
- 20 Yamazoe, Y., Kamataki, T., Kato, R. (1981b). Species difference in *N*-hydroxylation of a tryptophan pyrolysis product in relation to mutagenic activation. *Cancer Res* 41:4518-4522.
- 21 Yamazoe, Y., Kamataki, T., Kato, R. (1981c). A sensitive method for determination of biphenyl hydroxylase activities using high-performance liquid chromatography. *Anal Biochem* 111:126-130.
- 22 Yamazoe, Y., Numata, H., Yanagita, T. (1981d). Thebaine metabolites in the urine of rhesus monkeys. *Japan J Pharmacol* 31:433-442.
- 23 Yamazoe, Y., Tada, M., Kamataki, T., Kato, R. (1981e). Enhancement of binding of *N*-hydroxy-Trp-P-2 to DNA by seryl-tRNA synthetase. *Biochem Biophys Res Commun* 102:432-439.
- 24 Kamataki, T., Maeda, K., Yamazoe, Y., Nagai, T., Kato, R. (1982a). Evidence for the involvement of multiple forms of cytochrome P-450 in the occurrence of sex-related differences of drug metabolism in the rat. *Life Sci*

- 31:2603-2610.
- 25 Kamataki, T., Maeda, K., Yamazoe, Y., Nagai, T., Kato, R. 1982b. Partial characterization of a cytochrome P-450 responsible for the occurrence of sex difference of drug metabolism in the rat. In: Sato R, Kato R, editors. *Microsomes, Drug Oxidation and Drug Toxicities*. Tokyo and London: Japan Sci. Soc. Press and John Wiley and Sons. p 399-400.
- 26 Kamataki, T., Yamazoe, Y., Mita, S., Kato, R. 1982c. Mutagenic activation and covalent binding of 3-amino-1-methyl-5*H*-pyrido(4,3-*b*) indole (Trp-P-2) by microsomal and reconstituted cytochrome P-450 system. In: Sato R, Kato R, editors. *Microsomes, Drug Oxidation and Drug Toxicities*. Tokyo and London: Japan Sci. Soc. Press and John Wiley and Sons. p 463-470.
- 27 Kato, R., Yamazoe, Y., Ishii, K., Kamataki, T. 1982a. N-Hydroxylation of Mutagenic heterocyclic aromatic amines in protein pyrolysates by cytochrome P-450. In: Sugimura T, Kondo S, Takebe H, editors. *Environmental Mutagens and Carcinogens*. Tokyo and New York: Univ. of Tokyo Press and Alan R. Liss, Inc. p 505-509.
- 28 Kato, R., Yamazoe, Y., Ishii, K., Mita, S., Kamataki, T., Sugimura, T. 1982b. Metabolism of mutagenic amino- γ -carbolines in tryptophan pyrolysates. In: Snyder S, Parke DV, Kocsis JJ, Jollow DJ, Gibson CG, Witmer CM, editors. *Biological Reactive Intermediate II Part B*. New York: Plenum Publishing Co. p 997-1009.
- 29 Kato, R., Yamazoe, Y., Mita, S., Kamataki, T., Kubota, T., Hanatani, Y., Mahejima, K. (1982c). Decrease in the activity of hepatic microsomal drug-metabolizing enzymes in tumor-bearing nude mice. *Gann* 73:907-911.
- 30 Mita, S., Yamazoe, Y., Kamataki, T., Kato, R. (1982). Effects of ascorbic acid on the nonenzymatic binding to DNA and the mutagenicity of N-hydroxylated metabolite of a tryptophan-pyrolysis product. *Biochem Biophys Res Commun* 105:1396-1401.
- 31 Niwa, T., Yamazoe, Y., Kato, R. (1982). Metabolic activation of 2-amino-9*H*-pyrido[2,3-*b*]indole by rat-liver microsomes. *Mutat Res* 95:159-170.
- 32 Yamazoe, Y., Imai, Y., Mita, S., Ishii, K., Kamataki, T., Kato, R. 1982a.

- Species difference and involvement of low and high spin forms of cytochrome P-448 in the metabolic activation of amino acid pyrolysis products. In: Sato R, Kato R, editors. *Microsomes, Drug Oxidation and Drug Toxicities*. Tokyo and London: Japan Sci. Soc. Press and John Wiley and Sons. p 525-526.
- 33 Yamazoe, Y., Shimada, M., Kamataki, T., Kato, R. (1982b). Covalent binding of N-hydroxy-Trp-P-2 to DNA by cytosolic proline-dependent system. *Biochem Biophys Res Commun* 107:165-172.
- 34 Kamataki, T., Maeda, K., Matsuda, N., Ishii, K., Yamazoe, Y., Kato, R. (1983a). A high spin form of cytochrome P-448 highly purified from PCB-treated rats-II Characteristic requirement of cytochrome *b₅* for maximum activity. *Biochem Pharmacol* 32:2479-2483.
- 35 Kamataki, T., Maeda, K., Matsuda, N., Ishii, K., Yamazoe, Y., Kato, R. (1983b). A high spin form of cytochrome P-448 highly purified from PCB-treated rats-II. Characteristic requirement of cytochrome *b₅* for maximum activity. *Biochem Pharmacol* 32:2479-2483.
- 36 Kamataki, T., Maeda, K., Yamazoe, Y., Matsuda, N., Ishii, K., Kato, R. (1983c). A high-spin form of cytochrome P-450 highly purified from polychlorinated biphenyl-treated rats. *Mol Pharmacol* 24:146-155.
- 37 Kamataki, T., Maeda, K., Yamazoe, Y., Nagai, T., Kato, R. (1983d). Sex-difference of cytochrome P-450 in the rat: Purification, characterization, and quantitation of constitutive forms of cytochrome P-450 from liver microsomes of male and female rats. *Arch Biochem Biophys* 225:758-770.
- 38 Kato, R., Kamataki, T., Yamazoe, Y. 1983a. High spin cytochrome P-448 with high activity for mutagenic activation of aromatic amines. In: Hayes AW, Schnell RC, Miya TS, editors. *Developments in the Science and Practice of Toxicology*: Elsevier Science Publishers B. V. p 403-406.
- 39 Kato, R., Kamataki, T., Yamazoe, Y. 1983b. N-Hydroxylation of carcinogenic and mutagenic aromatic amines. *Environ Health Perspect.* p 21-25.
- 40 Mita, S., Yamazoe, Y., Kamataki, T., Kato, R. (1983). Metabolic activation of Trp-P-2, a tryptophan-pyrolysis mutagen, by isolated rat hepatocytes. *Biochem Pharmacol* 32:1179-1182.
- 41 Saito, K., Yamazoe, Y., Kamataki, T., Kato, R. (1983a). Activation and detoxication of N-hydroxy-Trp-P-2 by glutathione and glutathione

- transferases. *Carcinogenesis* 4:1551-1557.
- 42 Saito, K., Yamazoe, Y., Kamataki, T., Kato, R. (1983b). Mechanism of activation of proximate mutagens in Ames' tester strains: The acetyl CoA-dependent enzyme in *Salmonella typhimurium* TA98 deficient in TA98/1,8-DNP₆ catalyzes DNA binding as the cause of mutagenicity. *Biochem Biophys Res Commun* 116:141-147.
- 43 Saito, K., Yamazoe, Y., Kamataki, T., Kato, R. (1983c). Syntheses of hydroxyamino, nitroso and nitro derivatives of Trp-P-2 and Glu-P-1, amino acid pyrolysate mutagens and their direct mutagenicities toward *Salmonella typhimurium* TA98 and TA98NR. *Carcinogenesis* 4:1547-1550.
- 44 Saito, K., Yamazoe, Y., Kamataki, T., Kato, R. (1983d). Interactions between the active metabolite of tryptophan pyrolysate mutagen, N-hydroxy-Trp-P-2, and lipids: The role of lipid peroxides in the conversion of N-hydroxy-Trp-P-2 to non-reactive forms. *Chem Biol Interact* 45:295-304.
- 45 Yamazoe, Y., Shimada, M., Kamataki, T., Kato, R. (1983). Microsomal activation of 2-amino-3-methylimidazo[4,5-f]quinoline, a pyrolysate of sardine and beef extracts, to a mutagenic intermediate. *Cancer Res* 43:5768-5774.
- 46 Muraki, T., Yamazoe, Y., Kato, R. (1984). Inhibition of benzodiazepine and GABA receptor binding by amino- γ -carbolines and other amino acid pyrolysate mutagens. *Eur J Pharmacol* 98:35-44.
- 47 Saito, K., Yamazoe, Y., Kamataki, T., Kato, R. (1984). Glutathione transferase-mediated and non-enzymatic activation and detoxication of the N-hydroxy derivative of Trp-P-2, a potent pyrolysate promutagen. *Xenobiotica* 14:545-548.
- 48 Shinohara, A., Yamazoe, Y., Saito, K., Kamataki, T., Kato, R. (1984). Species differences in the N-acetylation by liver cytosol of mutagenic heterocyclic aromatic amines in protein pyrolysates. *Carcinogenesis* 5:683-686.
- 49 Yamazoe, Y., Shimada, M., Maeda, K., Kamataki, T., Kato, R. (1984). Specificity of four forms of cytochrome P-450 in the metabolic activation of several aromatic amines and benzo[a]pyrene. *Xenobiotica* 14:549-552.
- 50 Frederick, C. B., Hammons, G. J., Beland, F. A., Yamazoe, Y., Guengerich, F. P., Zenser, T. V., Ziegler, D. M., Kadlubar, F. F. 1985. N-Oxidation of

- primary aromatic amines in relation to chemical carcinogenesis. In: Gorrod, Damani, editors. Biological Oxidation of Nitrogen in Organic Molecules. Chichester: Ellis Horwood Limited. p 132-148.
- 51 Saito, K., Yamazoe, Y., Kamataki, T., Kato, R. (1985). Fast-atom bombardment and electron-impact mass spectrometry of N-hydroxyarylamines. *Xenobiotica* 15:327-332.
- 52 Shinohara, A., Saito, K., Yamazoe, Y., Kamataki, T., Kato, R. (1985). DNA binding of N-hydroxy-Trp-P-2 and N-hydroxy-Glu-P-1 by acetyl-CoA dependent enzyme in mammalian liver cytosol. *Carcinogenesis* 6:305-307.
- 53 Yamazoe, Y., Miller, D. W., Weis, C. C., Dooley, K. L., Zenser, T. V., Beland, F. A., Kadlubar, F. F. (1985a). DNA adducts formed by *ring* -oxidation of the carcinogen 2-naphthylamine with prostaglandin H synthase *in vitro* and in the dog urothelium *in vivo*. *Carcinogenesis* 6:1379-1387.
- 54 Yamazoe, Y., Shimada, M., Shinohara, A., Saito, K., Kamataki, T., Kato, R. (1985b). Catalysis of the covalent binding of 3-hydroxyamino-1-methyl-5*H*-pyrido[4,3-*b*]indole to DNA by a L-proline- and adenosine triphosphate-dependent enzyme in rat hepatic cytosol. *Cancer Res* 45:2495-2500.
- 55 Kadlubar, F. F., Yamazoe, Y., Lang, N. P., Chu, D. Z. J., Beland, F. A. 1986. Carcinogen-DNA adduct formation as a predictor of metabolic activation pathways and reactive intermediates in benzidine carcinogens. In: Kocsis JJ, Jollow DJ, Witmer CM, Nelson JO, Snyder R, editors. Biological Reactive Intermediates III Mechanisms of Action in Animal Models and Human Disease. New York and London: Plenum Press. p 537-549.
- 56 Kamataki, T., Yamazoe, Y., Kato, R. 1986. Alteration in population of sex-specific P-450 species in rat liver microsomes during aging. In: Kitani K, editor. Liver and Aging-1986: Elsevier Science Publishers B. V. p 15-27.
- 57 Kato, R., Yamazoe, Y. 1986. Metabolic activations of heterocyclic amines from protein pyrolysates: Significance for genotoxicity and carcinogenicity. In: Ruchirawat M, Shank RC, editors. Environmental Toxicity and Carcinogenicity. Bangkok: Texp and Journal Corp. p 69-79.
- 58 Kato, R., Yamazoe, Y., Shimada, M., Murayama, N., Kamataki, T. (1986). Effect of growth hormone and ectopic transplantation of pituitary gland on

- sex-specific forms of cytochrome P-450 and testosterone and drug oxidations in rat liver. *J Biochem* 100:895-902.
- 59 Shinohara, A., Saito, K., Yamazoe, Y., Kamataki, T., Kato, R. (1986a). Acetyl coenzyme A-dependent activation of N-hydroxy derivative of carcinogenic arylamines: Mechanism of activation, species difference, tissue distribution and acetyl donor specificity. *Cancer Res* 46:4362-4367.
- 60 Shinohara, A., Saito, K., Yamazoe, Y., Kamataki, T., Kato, R. (1986b). Inhibition of acetyl-coenzyme A dependent activation of N-hydroxyarylamines by phenolic compounds, pentachlorophenol and 1-nitro-2-naphthol. *Chem Biol Interact* 60:275-285.
- 61 Yamazoe, Y., Roth, R. W., Kadlubar, F. F. (1986a). Reactivity of benzidine diimine with DNA to form N-(deoxyguanosin-8-yl)-benzidine. *Carcinogenesis* 7:179-182.
- 62 Yamazoe, Y., Shimada, M., Kamataki, T., Kato, R. (1986b). Effect of hypophysectomy and growth hormone treatment on sex-specific forms of cytochrome P-450 in relation to drug and steroid metabolisms in rat liver microsomes. *Japan J Pharmacol* 42:371-382.
- 63 Yamazoe, Y., Shimada, M., Murayama, N., Kawano, S., Kato, R. (1986c). The regulation by growth hormone of microsomal testosterone 6 β -hydroxylase in male rat livers. *J Biochem* 100:1095-1097.
- 64 Flammang, T. J., Yamazoe, Y., Guengerich, F. P., Kadlubar, F. F. (1987). The S-acetyl coenzyme A-dependent metabolic activation of the carcinogen N-hydroxy-2-aminofluorene by human liver cytosol and its relationship to the aromatic amine N-acetyltransferase phenotype. *Carcinogenesis* 8:1967-1970.
- 65 Kato, R., Yamazoe, Y. (1987a). Metabolic activation and covalent binding to nucleic acids of carcinogenic heterocyclic amines from cooked foods and aminoacid pyrolysates. *Japan J Cancer Res* 78:297-311.
- 66 Kato, R., Yamazoe, Y. 1987b. Suppressive regulation by pituitary factors of the level of phenobarbital-inducible forms of cytochrome P-450 in rat livers. In: Sato R, Omura T, Imai Y, Fujii-Kuriyama Y, editors. *Cytochrome P-450: New Trends*: Yamada Science Foundation. p 131-148.
- 67 Kawano, S., Kamataki, T., Yasumori, T., Yamazoe, Y., Kato, R. (1987).

- Purification of human liver cytochrome P-450 catalyzing testosterone 6 β -hydroxylation. *J Biochem* 102:493-501.
- 68 Shimada, M., Murayama, N., Yamazoe, Y., Kamataki, T., Kato, R. (1987). Further studies on the persistence of neonatal androgen imprinting on sex-specific cytochrome P-450, testosterone and drug oxidations. *Japan J Pharmacol* 45:467-478.
- 69 Yamazoe, Y., Manabe, S., Murayama, N., Kato, R. (1987a). Regulation of hepatic sulfotransferase catalyzing the activation of N-hydroxyarylamide and N-hydroxyarylamine by growth hormone. *Mol Pharmacol* 32:536-541.
- 70 Yamazoe, Y., Shimada, M., Murayama, N., Kato, R. (1987b). Suppression of levels of phenobarbital-inducible rat liver cytochrome P-450 by pituitary hormone. *J Biol Chem* 262:7423-7428.
- 71 Yasumori, T., Kawano, S., Nagata, K., Shimada, M., Yamazoe, Y., Kato, R. (1987). Nucleotide sequence of a human liver cytochrome P-450 related to the rat male specific form. *J Biochem* 102:1075-1082.
- 72 Djurić, Z., Fifer, E. K., Yamazoe, Y., Beland, F. A. (1988). DNA binding by 1-nitropyrene and 1,6-dinitropyrene in vitro and in vivo : effects of nitroreductase induction. *Carcinogenesis* 9:357-364.
- 73 Kato, R., Yamazoe, Y. 1988a. Hormonal regulation of sex-specific forms of cytochrome P-450 involved in the hydroxylation of steroids and drugs. In: Miners JO, Birkett DJ, Drew R, May BK, McManus ME, editors. 7th International Symposium Microsomes and Drug Oxidation. Adelaide: Taylor & Francis. p 140-147.
- 74 Kato, R., Yamazoe, Y. 1988b. Hormonal regulation of sex-specific forms of cytochrome P-450 involved in the hydroxylation of steroid and drugs. In: Miners JO, Birkett DJ, Drew R, May BK, McManus ME, editors. Microsomal Drug Oxidations. p 140-147.
- 75 Kato, R., Yamazoe, Y. 1988c. N-Hydroxyarylamine O-acetyltransferase in mammalian livers and *Salmonella*. In: King CM, Romano LJ, Shuetzle D, editors. Carcinogenic and Mutagenic Responses to Aromatic amines and Nitroarenes. New York: Elsevier Science Publishing. p 125-136.
- 76 Kawakubo, Y., Manabe, S., Yamazoe, Y., Nishikawa, T., Kato, R. (1988). Properties of cutaneous acetyltransferase catalyzing N- and O-acetylation of

- carcinogenic arylamines and *N*-hydroxyarylamines. *Biochem Pharmacol* 37:265-270.
- 77 Niwa, T., Tokuma, Y., Nakagawa, K., Noguchi, H., Yamazoe, Y., Kato, R. (1988). Stereoselective oxidation and plasma-protein binding of nilvadipine, a new dihydropyridine calcium-antagonist. *Res Commun Chem Pathol Pharmacol* 60:161-172.
- 78 Yamazoe, Y., Abu-Zeid, M., Manabe, S., Toyama, S., Kato, R. (1988a). Metabolic activation of a protein pyrolysate promutagen 2-amino-3,8-dimethylimidazo[4,5-*f*]quinoxaline (MeIQx) by rat liver microsomes and purified cytochrome P-450. *Carcinogenesis* 9:105-109.
- 79 Yamazoe, Y., Abu-Zeid, M., Yamauchi, K., Kato, R. (1988b). Metabolic activation of pyrolysate arylamines by human liver microsomes: possible involvement of a P-448-H type cytochrome P-450. *Japan J Cancer Res* 79:1159-1167.
- 80 Yamazoe, Y., Abu-Zeid, M., Yamauchi, K., Murayama, N., Kato, R. (1988c). Enhancement by alloxan-induced diabetes of the rates of metabolic activation of three pyrolysate carcinogens via increase in the P-448-H content in rat liver. *Biochem Pharmacol* 37:2503-2506.
- 81 Yamazoe, Y., Murayama, N., Shimada, M., Yamauchi, K., Nagata, K., Imaoka, S., Funae, Y., Kato, R. (1988d). A sex-specific form of cytochrome P-450 catalyzing propoxycoumarin *O*-depropylation and its identity with testosterone 6 β -hydroxylase in untreated rat livers: Reconstitution of the activity with microsomal lipids. *J Biochem* 104:785-790.
- 82 Yamazoe, Y., Shimada, M., Yamauchi, K., Murayama, N., Kato, R. (1988e). Alteration of hepatic drug metabolizing activities and contents of cytochrome P-450 isozymes by neonatal monosodium glutamate treatment. *Biochem Pharmacol* 37:1687-1691.
- 83 Yamazoe, Y., Zenser, T. V., Miller, D. W., Kadlubar, F. F. (1988f). Mechanism of formation and structural characterization of DNA adducts derived from peroxidative activation of benzidine. *Carcinogenesis* 9:1635-1641.
- 84 Flammang, T. J., Yamazoe, Y., Benson, R. W., Roberts, D. W., Potter, D. W., Chu, D. W., Lang, D. Z. J., Kadlubar, F. F. (1989). Arachidonic

- acid-dependent peroxidative activation of carcinogenic arylamines by extrahepatic human tissue microsomes. *Cancer Res* 49:1977-1982.
- 85 Fukuhara, M., Nagata, K., Mizokami, K., Yamazoe, Y., Takanaka, A., Kato, R. (1989a). Complete cDNA sequence of a major 3-methylcholanthrene-inducible cytochrome P-450 isozyme (P-450AFB) of syrian-hamsters with high activity toward aflatoxin-B1. *Biochem Biophys Res Commun* 162:265-272.
- 86 Fukuhara, M., Nagata, K., Mizokami, K., Yamazoe, Y., Takanaka, A., Kato, R. (1989b). Complete cDNA sequence of a major 3-methylcholanthrene-inducible cytochrome P-450 isozyme (P-450AFB) of Syrian hamsters with high activity toward aflatoxin B1. *Biochem Biophys Res Commun* 162:265-272.
- 87 Hirota, K., Kawanishi, T., Sunouchi, M., Ohno, Y., Takanaka, A., Yamazoe, Y., Kato, R., Murakoshi, Y. (1989). Induction of cytochrome P-450c and P-450d by metyrapone in the primary culture of rat hepatocytes. *Japan J Pharmacol* 51:136-139.
- 88 Kato, R., Yamazoe, Y. 1989. Further metabolic activations of mutagenic and carcinogenic N-hydroxyarylamine by conjugating enzymes. In: Kato R, Estabrook RW, Cayen MN, editors. *Xenobiotic Metabolism and Disposition*. London: Taylor & Francis. p 383-391.
- 89 Miyata, M., Nagata, K., Yamazoe, Y., Kato, R. (1989). Isolation and characterization of human liver cytochrome b₅ cDNA. *Pharmacol Res* 21:513-520.
- 90 Nagata, K., Miyata, M., Shimada, M., Yamazoe, Y., Kato, R. (1989). Hepatic level of mRNA in relation to polymorphism and strain difference in expression of cytochrome P-450g. *Japan J Pharmacol* 51:585-588.
- 91 Ogura, K., Kajita, J., Narihata, H., Watabe, T., Ozawa, S., Nagata, K., Yamazoe, Y., Kato, R. (1989). Cloning and sequence analysis of a rat liver cDNA encoding hydroxysteroid sulfotransferase. *Biochem Biophys Res Commun* 165:168-174.
- 92 Shimada, M., Murayama, N., Yamauchi, K., Yamazoe, Y., Kato, R. (1989a). Suppression in the expression of a male-specific cytochrome P-450, P-450-male: Difference in the effect of chemical inducers on P450-male

- mRNA and protein in rat livers. *Arch Biochem Biophys* 270:578-587.
- 93 Shimada, M., Nagata, K., Murayama, N., Yamazoe, Y., Kato, R. (1989b). Role of growth hormone in modulating the constitutive and phenobarbital-induced levels of two P-450₆ (Testosterone 6 β -hydroxylase) mRNAs in rat livers. *J Biochem* 106:1030-1034.
- 94 Yamano, S., Nagata, K., Yamazoe, Y., Kato, R., Gelboin, H. V., Gonzalez, F. J. (1989). cDNA and deduced amino acid sequences of human P450 IIA3 (*CYP2A3*). *Nucleic Acids Research* 17:4888.
- 95 Yamazoe, Y., Abu-Zeid, M., Dawei, G., Staiano, N., Kato, R. (1989a). Enzymatic acetylation and sulfation of N-hydroxyarylamines in bacteria and rat livers. *Carcinogenesis* 10:1675-1679.
- 96 Yamazoe, Y., Gong, D., Murayama, N., Kato, R. (1989b). Regulation of hepatic cortisol sulfotransferase by pituitary hormone. *Mol Pharmacol* 35:707-712.
- 97 Yamazoe, Y., Murayama, N., Shimada, M., Imaoka, S., Funae, Y., Kato, R. (1989c). Suppression of hepatic levels of an ethanol-inducible P-450DM/j by growth hormone: Relationship between the increased level of P-450DM/j and depletion of growth hormone in diabetes. *Mol Pharmacol* 36:716-722.
- 98 Yamazoe, Y., Murayama, N., Shimada, M., Kato, R. (1989d). Thyroid hormone suppression of hepatic levels of phenobarbital-inducible P-450b and P-450e, and other neonatal P-450s in hypophysectomized rats by thyroid hormone. *Biochem Biophys Res Commun* 160:609-614.
- 99 Yamazoe, Y., Murayama, N., Shimada, M., Yamauchi, K., Kato, R. (1989e). Cytochrome P450 in livers of diabetic rats: Regulation by growth hormone and insulin. *Arch Biochem Biophys* 268:567-575.
- 100 Yamazoe, Y., Shimada, M., Murayama, N., Nagata, K., Kato, R. 1989f. Hormonal regulation of hepatic cytochrome P-450. In: Kato R, Estabrook RW, Cayen MN, editors. *Xenobiotic Metabolism and Disposition*. London: Taylor & Francis. p 37-44.
- 101 Yasumori, T., Murayama, N., Yamazoe, Y., Abe, A., Nogi, Y., Fukasawa, T., Kato, R. (1989). Expression of a human P-450IIC gene in yeast cells using galactose-inducible expression system. *Mol Pharmacol* 35:443-449.
- 102 Abu-Zeid, M., Staiano, N., Yamazoe, Y., Kato, R. (1990). Enhancement by

- cysteiny l thiols of acetyltransferase-mediated, but not of sulfotransferase-mediated, binding of a pyrolysate-derived N-hydroxyarylamine, 2-hydroxyamino-6-methyldipyrido[1,2-*a*:3',2'-*d*]imidazole, to DNA. *Japan J Cancer Res* 81:653-659.
- 103 Aoyama, T., Nagata, K., Yamazoe, Y., Kato, R., Matsunaga, E., Gelboin, H. V., Gonzalez, F. J. (1990). Cytochrome b₅ potentiation of P-450 catalytic activity demonstrated by a vaccinia virus-mediated *in situ* reconstituted system. *Proc Natl Acad Sci U S A* 87:5425-5429.
- 104 Kato, R., Yamazoe, Y. 1990a. Enzymic aspects on the metabolic activation of aromatic and heterocyclic amine mutagens in mammalian and bacterial cells. In: Kappas A, editor. *Mechanisms of Environmental Mutagenesis-Carcinogenesis*. New York: Plenum Press. p 211-221.
- 105 Kato, R., Yamazoe, Y. 1990b. Sex-dependent regulation of cytochrome P-450 expression. In: Ruckpaul K, Rein H, editors. *Frontiers in Biotransformation: Principles, Mechanisms and Biological Consequences of Induction*. Berlin: Akademie-Verlag. p 82-112.
- 106 Kawakubo, Y., Yamazoe, Y., Kato, R., Nishikawa, T. (1990). High capacity of human skin for N-acetylation of arylamines. *Skin Pharmacol* 3:180-185.
- 107 Nagata, K., Gonzalez, F. J., Yamazoe, Y., Kato, R. (1990a). Purification and characterization of four catalytically active testosterone 6 β -hydroxylase P-450s from rat liver microsomes: Comparison of a novel form with three structurally and functionally related forms. *J Biochem* 107:718-725.
- 108 Nagata, K., Sasamura, H., Miyata, M., Shimada, M., Yamazoe, Y., Kato, R. (1990b). cDNA and deduced amino acid sequences of a male dominant P-450M_d mRNA in rats. *Nucleic Acids Res* 18:4934.
- 109 Ogura, K., Kajita, J., Narihata, H., Watabe, T., Ozawa, S., Nagata, K., Yamazoe, Y., Kato, R. (1990). cDNA cloning of the hydroxysteroid sulfotransferase ST_a sharing a strong homology in amino acid sequence with the senescence marker protein SMP-2 in rat livers. *Biochem Biophys Res Commun* 166:1494-1500.
- 110 Ozawa, S., Abu-Zeid, M., Kawakubo, Y., Toyama, S., Yamazoe, Y., Kato, R. (1990a). Monomorphic and polymorphic isozymes of arylamine N-acetyltransferase in hamster liver: purification of the isozymes and

- genetic basis of N-acetylation polymorphism. *Carcinogenesis* 11:2137-2144.
- 111 Ozawa, S., Abu-Zeid, M., Murayama, N., Yamazoe, Y., Kato, R. (1990b). Decrease in the metabolic activating capacities of arylamines in livers bearing hyperplastic nodules: Association with the selective changes in hepatic P-450 isozymes. *Japan J Cancer Res* 81:247-252.
- 112 Ozawa, S., Nagata, K., Gong, D. W., Yamazoe, Y., Kato, R. (1990c). Nucleotide sequence of a full-length cDNA (PST-1) for aryl sulfotransferase from rat liver. *Nucleic Acids Res* 18:4001.
- 113 Sasamura, H., Nagata, K., Yamazoe, Y., Shimada, M., Saruta, T., Kato, R. (1990). Effect of growth hormone on rat hepatic cytochrome P-450f mRNA: a new mode of regulation. *Mol Cell Endocrinol* 68:53-60.
- 114 Yamazoe, Y., Ling, X., Murayama, N., Gong, D., Nagata, K., Kato, R. (1990). Modulation of hepatic level of microsomal testosterone 7 α -hydroxylase, P-450a (P450IIA), by thyroid hormone and growth hormone in rat liver. *J Biochem* 108:599-603.
- 115 Yasumori, T., Murayama, N., Yamazoe, Y., Kato, R. (1990). Polymorphism in hydroxylation of mephenytoin and hexobarbital stereoisomers in relation to hepatic P-450 human-2. *Clin Pharmacol Ther* 47:313-322.
- 116 Abu-Zeid, M., Nagata, K., Miyata, M., Ozawa, S., Fukuhara, M., Yamazoe, Y., Kato, R. (1991). An arylamine acetyltransferase (AT-I) from Syrian golden hamster liver: Cloning, complete nucleotide sequence, and expression in mammalian cells. *Mol Carcinog* 4:81-88.
- 117 Gong, D.-W., Ozawa, S., Yamazoe, Y., Kato, R. (1991). Purification of hepatic N-hydroxyarylamine sulfotransferases and their regulation by growth hormone and thyroid hormone in rats. *J Biochem* 110:226-231.
- 118 Kato, R., Yamazoe, Y. 1991. Purification, cloning and expression of hamster acetyltransferases which detoxify and activate chemicals and carcinogens. The first international conference. Environmental and industrial toxicology: research and applications; 1991; Bangkok Thailand. Chulabhorn research Institute. p. 333-347.
- 119 Kato, R., Yamazoe, Y., Yasumori, T. 1991a. Pharmacogenetics and polymorphism of human P-450 which activates and detoxicates xenobiotics and carcinogens. In: Ernster L, Esumi H, Fujii Y, Gelboin HV, Kato R,

- Sugimura T, editors. *Xenobiotics and Cancer Implications for Chemical Carcinogenesis and Cancer Chemotherapy*. Tokyo/London: Japan Sci. Press/Taylor & Francis. p 45-53.
- 120 Kato, R., Yasumori, T., Yamazoe, Y. 1991b. Characterization of human P450IIC isozyme by using a yeast expression system. In: Waterman MR, Johnson EF, editors. *Methods Enzymol.* Orlando FL.: Academic Press. p 183-190.
- 121 Ketterer, B., Meyer, D. J., Lalor, E., Johnson, P., Guengerich, F. P., Distlerath, L. M., Reilly, P. E. B., Kadlubar, F. F., Flammang, T. J., Yamazoe, Y., Beaune, P. H. (1991). A comparison of levels of glutathione transferases, cytochrome P450 and acetyltransferase in human livers. *Biochem Pharmacol* 41:635-638.
- 122 Miyata, M., Nagata, K., Yamazoe, Y., Kato, R. (1991). A gene structure of testosterone 6 β -hydroxylase(P450IIIA). *Biochem Biophys Res Commun* 177:68-73.
- 123 Murayama, N., Shimada, M., Yamazoe, Y., Kato, R. (1991). Difference in the susceptibility of two phenobarbital-inducible forms, P450IIB1 and P450IIB2, to thyroid hormone-induced and growth hormone-induced suppression in rat liver: Phenobarbital-inducible P450IIB2 suppression by thyroid hormone acting directly, but not through the pituitary system. *Mol Pharmacol* 39:811-817.
- 124 Nagata, K., Shimada, M., Yamazoe, Y., Kato, R. (1991). Regulations of male dominant P-450M δ mRNA in rat liver by hormonal factors and xenobiotics. *Japan J Pharmacol* 57:123-126.
- 125 Yamazoe, Y., Abu-Zeid, M., Gong, D.-W., Ozawa, S., Nagata, K., Kato, R. 1991. Acetyltransferase and sulfotransferase which activate mutagens and carcinogens through O-esterification mechanisms. In: Ernster L, Esumi H, Fujii Y, Gelboin HV, Kato R, Sugimura T, editors. *Xenobiotics and Cancer Implications for Chemical Carcinogenesis and Cancer Chemotherapy*. Tokyo/London: Japan Sci. Press/Taylor & Francis. p 109-117.
- 126 Yamazoe, Y., Ozawa, S. 1991. Activation of food mutagens. In: Hayatsu H, editor. *Mutagens in Food: Detection and Protection*. Boca Raton FL.: CRC Press. p 125-141.

- 127 Yasumori, T., Yamazoe, Y., Kato, R. (1991). Cytochrome P-450 human-2 (P-450IIC9) in mephenytoin hydroxylation polymorphism in human livers: Differences in substrate and stereoselectivities among microheterogeneous P-450IIC species expressed in yeast. *J Biochem* 109:711-717.
- 128 Abu-Zeid, M., Yamazoe, Y., Kato, R. (1992). Sulfotransferase-mediated DNA binding of N-hydroxyarylamines (amide) in liver cytosols from human and experimental animals. *Carcinogenesis* 13:1307-1314.
- 129 Gong, D. W., Murayama, N., Yamazoe, Y., Kato, R. (1992). Hepatic triiodothyronine sulfation and its regulation by growth hormone and triiodothyronine in rats. *J Biochem* 112:112-116.
- 130 Imaoka, S., Yamazoe, Y., Kato, R., Funae, Y. (1992). Hormonal regulation of rat renal cytochrome P450s by androgen and the pituitary. *Arch Biochem Biophys* 299:179-184.
- 131 Iwasaki, K., Shiraga, T., Matsuda, H., Noda, K., Yamazoe, Y., Nagata, K., Yasumori, T., Ozawa, S., Shimada, M., Murayama, N., Kato, R. (1992). Effect of repeated oral doses of a novel immunosuppressive macrolide lactone on hepatic mixed-function oxidase system in the rat Comparative study with ciclosporin. *Arzneimittelforschung* 42-1:340-344.
- 132 Kato, R., Yamazoe, Y. (1992). Sex-specific cytochrome P450 as a cause of sex- and species-related differences in drug toxicity. *Toxicol Lett* 64-5:661-667.
- 133 Kato, R., Yamazoe, Y., Yasumori, T. (1992). Polymorphism in stereoselective hydroxylations of mephenytoin and hexobarbital by Japanese liver samples in relation to cytochrome P-450 human-2 (IIC9). *Xenobiotica* 22:1083-1092.
- 134 Kawanishi, T., Ohno, Y., Takanaka, A., Kawano, S., Yamazoe, Y., Kato, R., Omori, Y. (1992). N-Nitrosodialkylamine dealkylation in reconstituted systems containing cytochrome P-450 purified from phenobarbital- and β -naphthoflavone-treated rats. *Arch Toxicol* 66:137-142.
- 135 Ando, M., Shindo, Y., Fujita, M., Ozawa, S., Yamazoe, Y., Kato, R. (1993). A new Salmonella tester strain expressing a hamster acetyltransferase shows high sensitivity for arylamines. *Mutat Res* 292:155-163.
- 136 Chen, L., Yasumori, T., Yamazoe, Y., Kato, R. (1993). Hepatic microsomal tolbutamide hydroxylation in Japanese: In vitro evidence for rapid and slow

- metabolizers. *Pharmacogenetics*. *Pharmacogenetics* 3:77-85.
- 137 Kato, R., Yamazoe, Y. 1993. Hormonal regulation of cytochrome P450 in rat liver. In: Schenkman JB, Greim H, editors. *Handbook of experimental Pharmacology*, 105 *Cytochrome P450*. Heidelberg: Springer-Verlag. p 447-459.
- 138 Nagata, K., Ozawa, S., Miyata, M., Shimada, M., Gong, D.-W., Yamazoe, Y., Kato, R. (1993). Isolation and expression of a cDNA encoding a male-specific rat sulfotransferase that catalyzes activation of N-hydroxy-2-acetylaminofluorene. *J Biol Chem* 268:24720-24725.
- 139 Ozawa, S., Nagata, K., Gong, D.-W., Yamazoe, Y., Kato, R. (1993). Expression and functional characterization of a rat sulfotransferase (ST1A1) cDNA for sulfations of phenolic substrates in COS-1 cells. *Japan J Pharmacol* 61:153-156.
- 140 Tainaka, H., Naito, T., Murayama, N., Yamazoe, Y., Kato, R. (1993). Modulation of ethanol-mediated CYP2E1 induction by clofibrate and L-carnitine in rat liver. *Biol Pharm Bull* 16:1240-1243.
- 141 Yamazoe, Y., Abu-Zeid, M., Staiano, N., Kato, R. 1993. Sulfotransferase- and acetyltransferase-mediated activation of carcinogenic N-hydroxyarylamines in mammals and bacteria, and their modulation by thiols. In: Bronzetti G, Hayatsu H, De Flora S, Waters MD, Shankel DM, editors. *Antimutagenesis and Anticarcinogenesis Mechanisms III*. New York: Plenum. p 161-169.
- 142 Yamazoe, Y., Kato, R. 1993. Activation of chemical carcinogens. In: Omura T, Ishimura Y, Fuji-Kuriyama Y, editors. *Cytochrome P-450*. Second ed. Tokyo: Kodansha/VCH. p 159-170.
- 143 Yasumori, T., Chen, L., Nagata, K., Yamazoe, Y., Kato, R. (1993a). Species differences in stereoselective metabolism of mephenytoin by cytochrome P450s (CYP2C and CYP3A). *J Pharmacol Exp Ther* 264:89-94.
- 144 Yasumori, T., Nagata, K., Yang, S. K., Chen, L.-S., Murayama, N., Yamazoe, Y., Kato, R. (1993b). Cytochrome P450 mediated metabolism of diazepam in human and rat: Involvement of human CYP2C in N-demethylation in concentration-dependent manner. *Pharmacogenetics* 3:291-301.
- 145 Kato, R., Yamazoe, Y. 1994a. Metabolic activation of N-hydroxylated metabolites of carcinogenic and mutagenic arylamines and arylamides by

- esterification. *Drug Metab Rev.* p 413-430.
- 146 Kato, R., Yamazoe, Y. (1994b). The importance of substrate concentration in determining cytochromes p450 therapeutically relevant in vivo. *Pharmacogenetics* 4:359-362.
- 147 Miyata, M., Nagata, K., Shimada, M., Yamazoe, Y., Kato, R. (1994). Structure of a gene and cDNA of a major constitutive form of testosterone 6 β -hydroxylase (P450/6 β A) encoding CYP3A2: Comparison of the cDNA with P450PCN2. *Arch Biochem Biophys* 314:351-359.
- 148 Nagata, K., Ozawa, S., Miyata, M., Shimada, M., Yamazoe, Y., Kato, R. (1994). Primary structure and molecular basis of polymorphic appearance of a hamster acetyltransferase, AT-II. *Pharmacogenetics* 4:91-100.
- 149 Ozawa, S., Chou, H.-C., Kadlubar, F. F., Nagata, K., Yamazoe, Y., Kato, R. (1994). Activation of 2-hydroxyamino-1-methyl-6-phenylimidazo[4,5-*b*]pyridine by cDNA-expressed human and rat arylsulfotransferases. *Japan J Cancer Res* 85:1220-1228.
- 150 Shiraga, T., Iwasaki, K., Nozaki, K., Tamura, T., Yamazoe, Y., Kato, R., Takataka, A. (1994). Isolation and characterization of four cytochrome P450 isozymes from untreated and penobarbital-treated beagle dogs. *Biol Pharm Bull* 17:22-28.
- 151 Yamazoe, Y., Murayama, Y., Shimada, M., Nagata, K., Ishikawa, H., Hashimoto, H., Nakayama, K., Sogawa, K., Fujii-Kuriyama, Y., Kato, R. 1994a. Hormonal influence on developmental changes in hepatic P450 in rat liver. In: Lechner MC, editor. *Cytochrome P450, Biochemistry, Biophysics and Molecular Biology*. Paris: John Libbey Eurotext. p 89-96.
- 152 Yamazoe, Y., Nagata, K., Ozawa, S., Kato, R. (1994b). Structural similarity and diversity of sulfotransferases. *Chem Biol Interact* 92:107-117.
- 153 Yamazoe, Y., Ozawa, S., Nagata, K., Gong, D.-W., Kato, R. (1994c). Characterization and expression of hepatic sulfotransferase involved in the metabolism of N-substituted aryl compounds. *Environ Health Perspect* 102(Suppl 6):99-103.
- 154 Yasumori, T., Ouing-Hua, L., Yamazoe, Y., Ueda, M., Tsuzuki, T., Kato, R. (1994). Lack of low Km diazepam N-demethylase in livers of poor metabolizers for S-mephenytoin 4'-hydroxylation. *Pharmacogenetics*

- 4:323-331.
- 155 Inaba, T., Alvan, G., Yamazoe, Y., Demorais, S. M. F., Goldstein, J. A., Tucker, G. T., Kato, R. 1995. Interethnic differences in drug metabolism and pharmacogenetics. In: Cuello AC, Collier B, editors. *Pharmacological Sciences: Perspectives for Research and Therapy in the Late 1990s*. PO Box 133, CH-4010 Basel, Switzerland: Birkhauser Verlag. p 169-175.
- 156 Kato, R., Yamazoe, Y. (1995). Molecular mechanisms of polymorphism in acetylating enzymes for arylamines and N-hydroxyarylamines in hamster liver. *Drug Metab Rev* 27:241-256.
- 157 Mackenzie, P. I., Anders, M. W., Yamazoe, Y., Weinshilboum, R. M., Knights, K. M., Caldwell, J. 1995. Drug conjugation: diversity and biological significance. In: Cuello AC, Collier B, editors. *Pharmacological Sciences: Perspectives for Research and Therapy in the Late 1990s*. PO Box 133, CH-4010 Basel, Switzerland: Birkhauser Verlag. p 161-168.
- 158 Miyata, M., Nagata, K., Yamazoe, Y., Kato, R. (1995). Transcriptional elements directing a liver-specific expression of P450/6 β -A (CYP3A2) gene-encoding testosterone 6 β -hydroxylase. *Arch Biochem Biophys* 318:71-79.
- 159 Ozawa, S., Nagata, K., Shimada, M., Ueda, M., Tsuzuki, T., Yamazoe, Y., Kato, R. (1995a). Primary structures and properties of two related forms of aryl sulfotransferases in human liver. *Pharmacogenetics* 5:S135-S140.
- 160 Ozawa, S., Nagata, K., Yamazoe, Y., Kato, R. (1995b). Formation of 2-amino-3-methylimidazo[4,5-f]quinoline- and 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline-sulfamates by cDNA-expressed mammalian phenol sulfotransferases. *Japan J Cancer Res* 86:264-269.
- 161 Sakamoto, K., Kirita, S., Baba, T., Nakamura, Y., Yamazoe, Y., Kato, R., Takanaka, A., Matsubara, T. (1995). A new cytochrome P450 form belonging to the CYP2D in dog liver microsomes: Purification, cDNA cloning, and enzyme characterization. *Arch Biochem Biophys* 319:372-382.
- 162 Sato, T., Murayama, N., Yamazoe, Y., Kato, R. (1995a). Suppression of clofibrate-induction of peroxisomal and microsomal fatty acid-oxidizing enzymes by growth hormone and thyroid hormone in primary cultures of rat

- hepatocytes. *Biochim Biophys Acta* 1256:327-333.
- 163 Sato, T., Murayama, N., Yamazoe, Y., Kato, R. (1995b). Effects of dicarboxylic acids on fatty acid-metabolizing enzymes in cultured rat hepatocytes. *Biol Pharm Bull* 18:1768-1769.
- 164 Shimada, M., Murayama, N., Yamazoe, Y., Hashimoto, H., Ishikawa, H., Kato, R. (1995). Age- and sex-related alterations of microsomal drug- and testosterone-oxidizing cytochrome P450 in Sprague-Dawley strain-derived dwarf rats. *J Pharmacol Exp Ther* 275:972-977.
- 165 Vatsis, K. P., Weber, W. W., Bell, D. A., Dupret, J.-M., Price Evans, D. A., Grant, D. M., Hein, D. W., Lin, H. J., Meyer, U. A., Relling, M. V., Sim, E., Suzuki, T., Yamazoe, Y. (1995). Nomenclature for N-acetyltransferases. *Pharmacogenetics* 5:1-17.
- 166 Yamazoe, Y., Kato, R. 1995. Structure and function of sulfotransferases. In: Pacifici GM, Fracchia GN, editors. *Advances in Drug Metabolism in Man*. Luxembourg: European Commission. p 659-678.
- 167 Yamazoe, Y., Nagata, K., Ozawa, S., Gong, D.-W., Kato, R. 1995. Activation and detoxication of carcinogenic arylamines by sulfation. In: Adamson RH, Gustafsson J-Å, Ito N, Nagao M, Sugimura T, Wakabayashi K, Yamazoe Y, editors. *Heterocyclic amines in cooked foods: Possible human carcinogens*. Princeton: Princeton Scientific Publishing. p 154-162.
- 168 Fujimaki, Y., Hakusui, H., Yamazoe, Y. (1996). Nefiracetam hydroxylation by rat liver microsomes and expressed human cytochrome P450s. *Xenobiotica* 26:821-830.
- 169 Glatt, H., Christoph, S., Czich, A., Pauly, K., Schwierzok, A., Seidel, A., Coughtrie, M. W. H., Doehmer, J., Falany, C. N., Phillips, D. H., Yamazoe, Y., Bartsch, I. 1996. Rat and human sulfotransferases expressed in Ames's *Salmonella typhimurium* strains and Chinese hamster V79 cells for the activation of mutagens. In: Hengstler JG, Oesch F, editors. *Control Mechanisms of Carcinogenesis*. Obere Zahlbacher Str 67, D-55131 Mainz, Germany: Institut Toxikologie. p 98-115.
- 170 Hojo, H., Sun, R., Ono, Y., Shishido, T., Obara, E., Yamazoe, Y., Hashimoto, Y. (1996). Differential production of interleukin-6 and its close relation to liver metastasis in clones from murine P815 mastocytoma. *Cancer Lett*

- 108:55-59.
- 171 Jiang, H., Yamamoto, S., Ozawa, S., Shimada, M., Yamazoe, Y., Kato, R. (1996). Inhibitory effect of TMK688 on skin tumor initiation caused by 7,12-dimethylbenz[a]anthracene in relation to inhibition of aryl hydrocarbon hydroxylase activity and *cyp1a1* mRNA induction. *Pharmacology* 53:123-132.
- 172 Kizaki, M., Ueno, H., Yamazoe, Y., Shimada, M., Takayama, N., Muto, A., Matsushita, H., Nakajima, H., Morikawa, M., Koeffler, H. P., Ikeda, Y. (1996). Mechanisms of retinoid resistance in leukemic cells: possible role of cytochrome P450 and p-glycoprotein. *Blood* 87:725-733.
- 173 Murayama, N., Shimada, M., Yamazoe, Y., Sogawa, K., Nakayama, K., Fujii-Kuriyama, Y., Kato, R. (1996). Distinct effects of phenobarbital and its N-methylated derivative on liver cytochrome P450 induction. *Arch Biochem Biophys* 328:184-192.
- 174 Nagata, K., Murayama, N., Miyata, M., Shimada, M., Urahashi, A., Yamazoe, Y., Kato, R. (1996). Isolation and characterization of a new rat P450 (CYP3A18) cDNA encoding P450_{6 β -2} catalyzing testosterone 6 β - and 16 α -hydroxylations. *Pharmacogenetics* 6:103-111.
- 175 O'brien, P. J., Hales, B. F., Josephy, P. D., Castonguay, A., Yamazoe, Y., Guengerich, F. P. (1996). Chemical carcinogenesis, mutagenesis, and teratogenesis. *Can J Physiol Pharmacol* 74:565-571.
- 176 Fujita, K., Nagata, K., Ozawa, S., Sasano, H., Yamazoe, Y. (1997). Molecular cloning and characterization of rat ST1B1 and human ST1B2 cDNAs, encoding thyroid hormone sulfotransferases. *J Biochem* 122:1052-1061.
- 177 Fukuda, K., Ohta, T., Oshima, Y., Ohashi, N., Yoshikawa, M., Yamazoe, Y. (1997a). Specific CYP3A4 inhibitors in grapefruit juice: furocoumarin dimers as components of drug interaction. *Pharmacogenetics* 7:391-396.
- 178 Fukuda, K., Ohta, T., Yamazoe, Y. (1997b). Grapefruit component interacting with rat and human CYP3A P450: Possible involvement of non-flavonoid components on drug interaction. *Biol Pharm Bull* 5:560-564.
- 179 Nagata, K., Yoshinari, K., Ozawa, S., Yamazoe, Y. (1997). Arylamine activating sulfotransferase in livers. *Mutat Res* 376:267-272.
- 180 Shimada, M., Murayama, N., Nagata, K., Hashimoto, H., Ishikawa, H.,

- Yamazoe, Y. (1997). A specific loss of growth hormone abolished sex-dependent expression of hepatic cytochrome P450 in dwarf rats: Reversal of the profiles by growth hormone-treatment. *Arch Biochem Biophys* 337:34-42.
- 181 Suzuki, E., Shintani, F., Nakaki, T., Nagata, K., Yamazoe, Y., Fujita, N., Asai, M., Kanba, S. (1997a). Dexamethasone and nitric oxide synthase gene expression in brain. *J Psychiatry Neurosci* 22:105-110.
- 182 Suzuki, S., Inoue, K., Hongoh, A., Hashimoto, Y., Yamazoe, Y. (1997b). Modulation of doxorubicin resistance in a doxorubicin-resistant human leukaemia cell by an immunoliposome targeting transferrin receptor. *Br J Cancer* 76:83-89.
- 183 Ueda, R., Shimada, M., Hashimoto, H., Ishikawa, H., Yamazoe, Y. (1997). Distinct regulation of two hydroxysteroid sulfotransferases, ST2A1 and ST2A2, by growth hormone: A unique type of growth hormone regulation in rats. *J Pharmacol Exp Ther* 282:1117-1121.
- 184 Alabouch, S., Kurose, K., Tohkin, M., Bani, M. H., Fukuhara, M., Nagata, K., Yamazoe, Y. (1998). cDNA cloning and expression of a novel CYP3A from the Syrian hamster, CYP3A31. *Biochim Biophys Acta* 1397:9-13.
- 185 Degawa, M., Nakayama, M., Konno, Y., Masubuchi, K., Yamazoe, Y. (1998). 2-methoxy-4-nitroaniline and its isomers induce cytochrome P4501A (CYP1A) enzymes with different selectivities in the rat liver. *Biochim Biophys Acta* 1379:391-398.
- 186 Glatt, H., Bartsch, I., Christoph, S., Coughtrie, M. W. H., Falany, C. N., Hagen, M., Landsiedel, R., Pabel, U., Phillips, D. H., Seidel, A., Yamazoe, Y. (1998). Sulfotransferase-mediated activation of mutagens studied using heterologous expression systems. *Chem Biol Interact* 109:195-219.
- 187 Ozawa, S., Tang, Y. M., Yamazoe, Y., Kato, R., Lang, N. P., Kadlubar, F. F. (1998). Genetic polymorphisms in human liver phenol sulfotransferases involved in the bioactivation of N-hydroxy derivatives of carcinogenic arylamines and heterocyclic amines. *Chem Biol Interact* 109:237-248.
- 188 Yoshinari, K., Nagata, K., Ogino, M., Fujita, K., Shiraga, T., Iwasaki, K., Hata, T., Yamazoe, Y. (1998a). Molecular cloning and expression of an amine sulfotransferase cDNA: A new gene family of cytosolic sulfotransferases in

- mammals. *J Biochem* 123:479-486.
- 189 Yoshinari, K., Nagata, K., Shimada, M., Yamazoe, Y. (1998b). Molecular characterization of ST1C1-related human sulfotransferase. *Carcinogenesis* 19:951-953.
- 190 Yoshinari, K., Nagata, K., Shiraga, T., Iwasaki, K., Hata, T., Ogino, M., Ueda, R., Fujita, K., Shimada, M., Yamazoe, Y. (1998c). Molecular cloning, expression, and enzymatic characterization of rabbit hydroxysteroid sulfotransferase AST-RB2 (ST2A8). *J Biochem* 123:740-746.
- 191 Fujita, K., Nagata, K., Watanabe, E., Shimada, M., Yamazoe, Y. (1999a). Bacterial expression and functional characterization of a rat thyroid hormone sulfotransferase, ST1B1. *Japan J Pharmacol* 79:467-475.
- 192 Fujita, K., Nagata, K., Yamazaki, T., Watanabe, E., Shimada, M., Yamazoe, Y. (1999b). Enzymatic characterization of human cytosolic sulfotransferases; identification of ST1B2 as a thyroid hormone sulfotransferase. *Biol Pharm Bull* 22:446-452.
- 193 Nagata, K., Ogino, M., Shimada, M., Miyata, M., Gonzalez, F. J., Yamazoe, Y. (1999). Structure and expression of the rat CYP3A1 gene: Isolation of the gene (P450/6bB) and characterization of the recombinant protein. *Arch Biochem Biophys* 362:242-253.
- 194 Ogino, M., Nagata, K., Miyata, M., Yamazoe, Y. (1999). Hepatocyte nuclear factor 4-mediated activation of rat CYP3A1 gene and its modes of modulation by apolipoprotein AI regulatory protein I and v-ErbA-related protein 3. *Arch Biochem Biophys* 362:32-37.
- 195 Shimada, M., Watanabe, E., Iida, Y., Nagata, K., Yamazoe, Y. (1999). Alteration of hepatic sulfation by endotoxin. *Japan J Pharmacol* 80:371-373.
- 196 Shiraga, T., Hata, T., Yamazoe, Y., Ohno, Y., Iwasaki, K. (1999a). N-sulphoconjugation of amines by human cytosolic hydroxysteroid sulphotransferase. *Xenobiotica* 29:341-347.
- 197 Shiraga, T., Iwasaki, K., Hata, T., Yoshinari, K., Nagata, K., Yamazoe, Y., Ohno, Y. (1999b). Purification and characterization of two amine N-sulfotransferases, AST-RB1 (ST3A1) and AST-RB2 (ST2A8), from liver cytosols of male rabbits. *Arch Biochem Biophys* 362:265-274.
- 198 Taniguchi, M., Xiao, Y.-Q., Liu, X.-H., Yabu, A., Hada, Y., Guo, L.-Q.,

- Yamazoe, Y., Baba, K. (1999). Rivulobirin E and Rivulotririn C from *Pleurospermum rivulorum*. *Chem Pharm Bull* 47:713-715
- 199 Yamazoe, Y., Nagata, K., Yoshinari, K., Fujita, K., Shiraga, T., Iwasaki, K. (1999). Sulfotransferase catalyzing sulfation of heterocyclic amines. *Cancer Lett* 143:103-107.
- 200 Yasumori, T., Chen, L. S., Li, Q. H., Ueda, M., Tsuzuki, T., Goldstein, J. A., Kato, R., Yamazoe, Y. (1999). Human CYP2C-mediated stereoselective phenytoin hydroxylation in Japanese: difference in chiral preference of CYP2C9 and CYP2C19. *Biochem Pharmacol* 57:1297-1303.
- 201 Fukuda, K., Guo, L., Ohashi, N., Yoshikawa, M., Yamazoe, Y. (2000). Amounts and variation in grapefruit juice of the main components causing grapefruit-drug interaction. *J Chromatogr B Biomed Sci Appl* 741:195-203.
- 202 Guo, L. Q., Fukuda, K., Ohta, T., Yamazoe, Y. (2000a). Role of furanocoumarin derivatives on grapefruit juice-mediated inhibition of human CYP3A activity. *Drug Metab Dispos* 28:766-771.
- 203 Guo, L. Q., Taniguchi, M., Xiao, Y. Q., Baba, K., Ohta, T., Yamazoe, Y. (2000b). Inhibitory effect of natural furanocoumarins on human microsomal cytochrome P450 3A activity. *Japan J Pharmacol* 82:122-129.
- 204 Hojo, M., Hanioka, K., Miyata, M., Yamazoe, Y. (2000). Hepatotoxicity of acetaminophen and N-acetyl-p-benzoquinone imine and enhancement by fructose. *Xenobiotica* 30:933-941.
- 205 Kato, R., Yamazoe, Y. (2000). History of drug metabolism research in Japan. *Drug Metab Rev* 32:45-79.
- 206 Nagata, K., Yamazoe, Y. (2000). Pharmacogenetics of sulfotransferase. *Ann Rev Pharmacol Toxicol* 40:159-176.
- 207 Nakamura, T., Okada, K., Nagata, K., Yamazoe, Y. (2000). Intestinal cytochrome P450 and response to rifampicin in rabbits. *Japan J Pharmacol* 82:232-239.
- 208 Tassaneeyakul, W., Guo, L. Q., Fukuda, K., Ohta, T., Yamazoe, Y. (2000a). Inhibition selectivity of grapefruit juice components on human cytochromes P450. *Arch Biochem Biophys* 378:356-363.
- 209 Tassaneeyakul, W., Vannaprasaht, S., Yamazoe, Y. (2000b). Formation of omeprazole sulphone but not 5-hydroxyomeprazole is inhibited by grapefruit

- juice. *Br J Clin Pharmacol* 49:139-144.
- 210 Yamazoe, Y., Nagata, K. 2000. In vitro Metabolism. In: Nagao M, Sugimura T, editors. Food borne carcinogens: Heterocyclic amines: John Willey & Sons p74-89.
- 211 Guo, L. Q., Taniguchi, M., Chen, Q. Y., Baba, K., Yamazoe, Y. (2001). Inhibitory potential of herbal medicines on human cytochrome P450-mediated oxidation: properties of umbelliferous or citrus crude drugs and their relative prescriptions. *Japan J Pharmacol* 85:399-408.
- 212 Honma, W., Kamiyama, Y., Yoshinari, K., Sasano, H., Shimada, M., Nagata, K., Yamazoe, Y. (2001). Enzymatic characterization and interspecies difference of phenol sulfotransferases, ST1A forms. *Drug Metab Dispos* 29:274-281.
- 213 Matsumoto, S., Yamazoe, Y. (2001). Involvement of multiple human cytochromes P450 in the liver microsomal metabolism of astemizole and a comparison with terfenadine. *Br J Clin Pharmacol* 51:133-142.
- 214 Miyata, M., Furukawa, M., Takahashi, K., Gonzalez, F. J., Yamazoe, Y. (2001). Mechanism of 7,12-dimethylbenz[a]anthracene-induced immunotoxicity: role of metabolic activation at the target organ. *Japan J Pharmacol* 86:302-309.
- 215 Shimada, M., Yoshinari, K., Tanabe, E., Shimakawa, E., Kobashi, M., Nagata, K., Yamazoe, Y. (2001). Identification of ST2A1 as a rat brain neurosteroid sulfotransferase mRNA. *Brain Res* 920:222-225.
- 216 Baba, T., Touchi, A., Ito, K., Yamaguchi, Y., Yamazoe, Y., Ohno, Y., Sugiyama, Y. (2002). Effects of serum albumin and liver cytosol on CYP2C9- and CYP3A4-mediated drug metabolism. *Drug Metab Pharmacokinet* 17:522-531.
- 217 Furukawa, M., Okubo, T., Ogino, M., Yamazaki, T., Shimada, M., Nagata, K., Yamazoe, Y. (2002). Adenovirus vector-mediated reporter system for in vivo analyses of human CYP3A4 gene activation. *J Biochem* 131:71-78.
- 218 Honma, W., Shimada, M., Sasano, H., Ozawa, S., Miyata, M., Nagata, K., Ikeda, T., Yamazoe, Y. (2002). Phenol sulfotransferase, ST1A3, as the main enzyme catalyzing sulfation of troglitazone in human liver. *Drug Metab Dispos* 30:944-949.

- 219 Maruyama, T., Nagahashi, M., Miyamoto, Y., Hosoi, S., Kiuchi, F., Yamazoe, Y., Tsukamoto, S. (2002). Paradisin C: a new CYP3A4 inhibitor from grapefruit juice. *Tetrahedron Lett* 58:6631-6635.
- 220 Matsumoto, S., HIRAMA, T., Matsubara, T., Nagata, K., Yamazoe, Y. (2002). Involvement of CYP2J2 on the intestinal first-pass metabolism of antihistamine drug, astemizole. *Drug Metab Dispos* 30:1240-1245.
- 221 Miyata, M., Motoki, K., Tamura, E., Furukawa, M., Gonzalez, F. J., Yamazoe, Y. (2002a). Relative importance of maternal and embryonic microsomal epoxide hydrolase in 7,12-dimethylbenz[a]anthracene-induced developmental toxicity. *Biochem Pharmacol* 63:1077-1084.
- 222 Miyata, M., Takano, H., Takahashi, K., Sasaki, Y. F., Yamazoe, Y. (2002b). Suppression of 2-amino-1-methyl-6-phenylimidazo [4,5-b]pyridine-induced DNA damage in rat colon after grapefruit juice intake. *Cancer Lett* 183:17-22.
- 223 Miyata, M., Tamura, E., Yamazoe, Y. (2002c). Development of an in vitro system detecting pro-embryotoxin. *Japan J Pharmacol* 89:320-323.
- 224 Nagata, K., Yamazoe, Y. (2002). Genetic polymorphism of human cytochrome P450 involved in drug metabolism. *Drug Metab Pharmacokinet* 17:167-189.
- 225 Ogino, M., Nagata, K., Yamazoe, Y. (2002). Selective suppressions of human CYP3A forms, CYP3A5 and CYP3A7, by troglitazone in HepG2 cells. *Drug Metab Pharmacokinet* 17:42-46.
- 226 Shimada, M., Kamiyama, Y., Sato, A., Honma, W., Nagata, K., Yamazoe, Y. (2002). A hydroxysteroid sulfotransferase, st2b2, is a skin cholesterol sulfotransferase in mice. *J Biochem* 131:167-169.
- 227 Kitada, H., Miyata, M., Nakamura, T., Tozawa, A., Honma, W., Shimada, M., Nagata, K., Sinal, C. J., Guo, G. L., Gonzalez, F. J., Yamazoe, Y. (2003). Protective role of hydroxysteroid sulfotransferase in lithocholic acid-induced liver toxicity. *J Biol Chem* 278:17838-17844.
- 228 Matsumoto, S., HIRAMA, T., Kim, H. J., Nagata, K., Yamazoe, Y. (2003). In vitro inhibition of human small intestinal and liver microsomal astemizole O-demethylation: different contribution of CYP2J2 in the small intestine and liver. *Xenobiotica* 33:615-623.

- 229 Miyata, M., Tamura, E., Motoki, K., Nagata, K., Yamazoe, Y. (2003). Thalidomide-induced suppression of embryo fibroblast proliferation requires CYP1A1-mediated activation. *Drug Metab Dispos* 31:469-475.
- 230 Yamamoto, T., Hagima, N., Fukasawa, M., Yamaguchi, J., Nakamura, M., Kohno, Y., Nagata, K., Yamazoe, Y. (2003a). Metabolism of N,N-dipropyl-2-[4-methoxy-3-(2-phenylethoxy)-phenyl]-ethyl-amine-monohydrochloride (NE-100), a novel sigma ligand: contribution of cytochrome P450 forms involved in the formation of individual metabolites in human liver and small intestine. *Drug Metab Pharmacokinet* 18:173-185.
- 231 Yamamoto, T., Hagima, N., Nakamura, M., Kohno, Y., Nagata, K., Yamazoe, Y. (2003b). Differences in cytochrome P450 forms involved in the metabolism of N,N-dipropyl-2-[4-methoxy-3-(2-phenylethoxy)-phenyl]ethylamine monohydrochloride (NE-100), a novel sigma ligand, in human liver and intestine. *Drug Metab Dispos* 31:60-66.
- 232 Guo, L. Q., Bao, H., Yang, J. T., Chen, Q. Y., Liu, Y. X., Li, J. H., Yamazoe, Y. (2004). Correlation of furanocoumarin composition and rat cytochrome P4503A inhibition among citrus fruit juices. *China J Clin Pharmacol Ther* 9:970-977.
- 233 Guo, L. Q., Yamazoe, Y. (2004). Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines. *Acta Pharmacol Sin* 25:129-136.
- 234 Maeda, T., Miyata, M., Yotsumoto, T., Kobayashi, D., Nozawa, T., Toyama, K., Gonzalez, F. J., Yamazoe, Y., Tamai, I. (2004). Regulation of drug transporters by the farnesoid X receptor in mice. *Mol Pharm* 1.
- 235 Matsubara, T., Kim, H. J., Miyata, M., Shimada, M., Nagata, K., Yamazoe, Y. (2004). Isolation and characterization of a new major intestinal CYP3A form, CYP3A62, in the rat. *J Pharmacol Exp Ther* 309:1282-1290.
- 236 Miyata, M., Takano, H., Guo, L. Q., Nagata, K., Yamazoe, Y. (2004). Grapefruit juice intake does not enhance but rather protects against aflatoxin B1-induced liver DNA damage through a reduction in hepatic CYP3A activity. *Carcinogenesis* 25:203-209.
- 237 Shimada, M., Terazawa, R., Kamiyama, Y., Honma, W., Nagata, K., Yamazoe, Y. (2004). Unique properties of a renal sulfotransferase, St1d1, in

- dopamine metabolism. *J Pharmacol Exp Ther* 310:808-814.
- 238 Takada, T., Ogino, M., Miyata, M., Shimada, M., Nagata, K., Yamazoe, Y. (2004). Differences in transactivation between rat CYP3A1 and human CYP3A4 genes by human pregnane X receptor. *Drug Metab Pharmacokinet* 19:103-113.
- 239 Yamamoto, T., Hagima, N., Nakamura, M., Kohno, Y., Nagata, K., Yamazoe, Y. (2004). Prediction of differences in in vivo oral clearance of N,N-dipropyl-2-[4-methoxy-3-(2-phenylethoxy)phenyl] ethylamine monohydrochloride (NE-100) between extensive and poor metabolizers from in vitro metabolic data in human liver microsomes lacking CYP2D6 activity and recombinant CYPs. *Xenobiotica* 34:687-703.
- 240 Ando, H., Tsuruoka, S., Yanagihara, H., Sugimoto, K., Miyata, M., Yamazoe, Y., Takamura, T., Kaneko, S., Fujimura, A. (2005). Effects of grapefruit juice on the pharmacokinetics of pitavastatin and atorvastatin. *Br J Clin Pharmacol* 60:494-497.
- 241 Miyata, M., Tozawa, A., Otsuka, H., Nakamura, T., Nagata, K., Gonzalez, F. J., Yamazoe, Y. (2005). Role of farnesoid X receptor in the enhancement of canalicular bile acid output and excretion of unconjugated bile acids: a mechanism for protection against cholic acid-induced liver toxicity. *J Pharmacol Exp Ther* 312:759-766.
- 242 Nagata, K., Shimada, M., Yamazoe, Y. 2005. Species differences in cytosolic sulfotransferases. In: Pacifici GM, Coughtrie MWH, editors. *Human Cytosolic Sulfotransferases*. . CRC Pr. p 253-278.
- 243 Takeda, S., Ishii, Y., Iwanaga, M., Mackenzie, P. I., Nagata, K., Yamazoe, Y., Oguri, K., Yamada, H. (2005a). Modulation of UDP-glucuronosyltransferase function by cytochrome P450: evidence for the alteration of UGT2B7-catalyzed glucuronidation of morphine by CYP3A4. *Mol Pharmacol* 67:665-672.
- 244 Takeda, S., Ishii, Y., Mackenzie, P. I., Nagata, K., Yamazoe, Y., Oguri, K., Yamada, H. (2005b). Modulation of UDP-glucuronosyltransferase 2B7 function by cytochrome P450s in vitro: differential effects of CYP1A2, CYP2C9 and CYP3A4. *Biol Pharm Bull* 28:2026-2027.
- 245 Yamamoto, T., Itoga, H., Kohno, Y., Nagata, K., Yamazoe, Y. (2005).

- Prediction of oral clearance from in vitro metabolic data using recombinant CYPs: comparison among well-stirred, parallel-tube, distributed and dispersion models. *Xenobiotica* 35:627-646.
- 246 Goda, R., Nagai, D., Akiyama, Y., Nishikawa, K., Ikemoto, I., Aizawa, Y., Nagata, K., Yamazoe, Y. (2006). Detection of a new N-oxidized metabolite of flutamide, N-[4-nitro-3-(trifluoromethyl)phenyl] hydroxylamine, in human liver microsomes and urine of prostate cancer patients. *Drug Metab Dispos* 34:828-835.
- 247 Itoh, M., Nakajima, M., Higashi, E., Yoshida, R., Nagata, K., Yamazoe, Y., Yokoi, T. (2006). Induction of human CYP2A6 is mediated by the pregnane X receptor with peroxisome proliferator-activated receptor- γ coactivator 1 α . *J Pharmacol Exp Ther* 319:693-702.
- 248 Miyata, M., Matsuda, Y., Tsuchiya, H., Kitada, H., Akase, T., Shimada, M., Nagata, K., Gonzalez, F. J., Yamazoe, Y. (2006a). Chenodeoxycholic acid-mediated activation of the farnesoid X receptor negatively regulates hydroxysteroid sulfotransferase. *Drug Metab Pharmacokinet* 21:315-323.
- 249 Miyata, M., Watase, H., Hori, W., Shimada, M., Nagata, K., Gonzalez, F. J., Yamazoe, Y. (2006b). Role for enhanced faecal excretion of bile acid in hydroxysteroid sulfotransferase-mediated protection against lithocholic acid-induced liver toxicity. *Xenobiotica* 36:631-644.
- 250 Noracharttiyapot, W., Nagai, Y., Matsubara, T., Miyata, M., Shimada, M., Nagata, K., Yamazoe, Y. (2006). Construction of several human-derived stable cell lines displaying distinct profiles of CYP3A4 induction. *Drug Metab Pharmacokinet* 21:99-108.
- 251 Ueda, R., Iketaki, H., Nagata, K., Kimura, S., Gonzalez, F. J., Kusano, K., Yoshimura, T., Yamazoe, Y. (2006). A common regulatory region functions bidirectionally in transcriptional activation of the human CYP1A1 and CYP1A2 genes. *Mol Pharmacol* 69:1924-1930.
- 252 Yamamoto, T., Suzuki, A., Kohno, Y., Nagata, K., Yamazoe, Y. (2006). Prediction of drug-drug interactions for AUC_{oral} of high clearance drug from in vitro data: utilization of a microtiter plate assay and a dispersion model. *Curr Drug Metab* 7:135-146.
- 253 Guo, L. Q., Chen, Q. Y., Wang, X., Liu, Y. X., Chu, X. M., Cao, X. M., Li, J. H.,

- Yamazoe, Y. (2007). Different roles of pummelo furanocoumarin and cytochrome P450 3A5*3 polymorphism in the fate and action of felodipine. *Curr Drug Metab* 8:623-630.
- 254 Ishii, Y., Iwanaga, M., Nishimura, Y., Takeda, S., Ikushiro, S., Nagata, K., Yamazoe, Y., Mackenzie, P. I., Yamada, H. (2007). Protein-protein interactions between rat hepatic cytochromes P450 (P450s) and UDP-glucuronosyltransferases (UGTs): evidence for the functionally active UGT in P450-UGT complex. *Drug Metab Pharmacokinet* 22:367-376.
- 255 Itoh, K., Masubuchi, A., Sasaki, T., Adachi, M., Watanabe, N., Nagata, K., Yamazoe, Y., Hiratsuka, M., Mizugaki, M., Tanaka, Y. (2007). Genetic polymorphism of aldehyde oxidase in Donryu rats. *Drug Metab Dispos* 35:734-739.
- 256 Kamiyama, Y., Matsubara, T., Yoshinari, K., Nagata, K., Kamimura, H., Yamazoe, Y. (2007). Role of human hepatocyte nuclear factor 4alpha in the expression of drug-metabolizing enzymes and transporters in human hepatocytes assessed by use of small interfering RNA. *Drug Metab Pharmacokinet* 22:287-298.
- 257 Kojima, K., Nagata, K., Matsubara, T., Yamazoe, Y. (2007). Broad but distinct role of pregnane x receptor on the expression of individual cytochrome P450s in human hepatocytes. *Drug Metab Pharmacokinet* 22:276-286.
- 258 Maeda, T., Oyabu, M., Yotsumoto, T., Higashi, R., Nagata, K., Yamazoe, Y., Tamai, I. (2007). Effect of pregnane X receptor ligand on pharmacokinetics of substrates of organic cation transporter Oct1 in rats. *Drug Metab Dispos* 35:1580-1586.
- 259 Matsubara, T., Noracharttiyapot, W., Toriyabe, T., Yoshinari, K., Nagata, K., Yamazoe, Y. (2007). Assessment of human pregnane X receptor involvement in pesticide-mediated activation of CYP3A4 gene. *Drug Metab Dispos* 35:728-733.
- 260 Nomoto, M., Miyata, M., Shimada, M., Yoshinari, K., Gonzalez, F. J., Shibasaki, S., Kurosawa, T., Shindo, Y., Yamazoe, Y. (2007). ME3738 protects against lithocholic acid-induced hepatotoxicity, which is associated with enhancement of biliary bile acid and cholesterol output. *Eur J*

- Pharmacol 574:192-200.
- 261 Matsubara, T., Yoshinari, K., Aoyama, K., Sugawara, M., Sekiya, Y., Nagata, K., Yamazoe, Y. (2008). Role of vitamin D receptor in the lithocholic acid-mediated CYP3A induction in vitro and in vivo. *Drug Metab Dispos* 36:2058-2063.
- 262 Senggunprai, L., Yoshinari, K., Shimada, M., Yamazoe, Y. (2008). Involvement of ST1B subfamily of cytosolic sulfotransferase in kynurenine metabolism to form natriuretic xanthurenic acid sulfate. *J Pharmacol Exp Ther* 327:789-798.
- 263 Shimada, M., Matsuda, T., Sato, A., Akase, T., Matsubara, T., Nagata, K., Yamazoe, Y. (2008). Expression of a skin cholesterol sulfotransferase, St2b2, is a trigger of epidermal cell differentiation. *Xenobiotica* 38:1487-1499.
- 264 Yoshinari, K., Ueda, R., Kusano, K., Yoshimura, T., Nagata, K., Yamazoe, Y. (2008). Omeprazole transactivates human CYP1A1 and CYP1A2 expression through the common regulatory region containing multiple xenobiotic-responsive elements. *Biochem Pharmacol* 76:139-145.
- 265 Aoyama, K., Yoshinari, K., Kim, H. J., Nagata, K., Yamazoe, Y. (2009). Simultaneous expression of plural forms of human cytochrome P450 at desired ratios in HepG2 cells: adenovirus-mediated tool for cytochrome P450 reconstitution. *Drug Metab Pharmacokinet* 24:209-217.
- 266 Li, Z., Okano, S., Yoshinari, K., Miyamoto, T., Yamazoe, Y., Shinya, K., Ioku, K., Kasai, N. (2009). Soft-hydrothermal processing of red cedar bedding reduces its induction of cytochrome P450 in mouse liver. *Lab Anim* 43:205-211.
- 267 Miyata, M., Matsuda, Y., Nomoto, M., Takamatsu, Y., Sato, N., Hamatsu, M., Dawson, P. A., Gonzalez, F. J., Yamazoe, Y. (2009a). Cholesterol feeding prevents hepatic accumulation of bile acids in cholic acid-fed Fxr-null mice: FXR-independent suppression of intestinal bile acid absorption. *Drug Metab Dispos* 37:338-344.
- 268 Miyata, M., Takamatsu, Y., Kuribayashi, H., Yamazoe, Y. (2009b). Administration of ampicillin elevates hepatic primary bile acid synthesis through suppression of ileal fibroblast growth factor 15 expression. *J Pharmacol Exp Ther* 331:1079-1085.

- 269 Nomoto, M., Miyata, M., Yin, S., Kurata, Y., Shimada, M., Yoshinari, K., Gonzalez, F. J., Suzuki, K., Shibasaki, S., Kurosawa, T., Yamazoe, Y. (2009). Bile acid-induced elevated oxidative stress in the absence of farnesoid X receptor. *Biol Pharm Bull* 32:172-178.
- 270 Ohbuchi, M., Miyata, M., Nagai, D., Shimada, M., Yoshinari, K., Yamazoe, Y. (2009). Role of enzymatic N-hydroxylation and reduction in flutamide metabolite-induced liver toxicity. *Drug Metab Dispos* 37:97-105.
- 271 Senggunprai, L., Yoshinari, K., Yamazoe, Y. (2009a). Selective role of sulfotransferase 2A1 (SULT2A1) in the N-sulfoconjugation of quinolone drugs in humans. *Drug Metab Dispos* 37:1711-1717.
- 272 Senggunprai, L., Yoshinari, K., Yamazoe, Y. (2009b). Inhibitory effects of kynurenic acid, a tryptophan metabolite, and its derivatives on cytosolic sulfotransferases. *Biochem J* 27:455-462.
- 273 Tachibana, S., Yoshinari, K., Chikada, T., Toriyabe, T., Nagata, K., Yamazoe, Y. (2009). Involvement of Vitamin D receptor in the intestinal induction of human ABCB1. *Drug Metab Dispos* 37:1604-1610.
- 274 Takeda, S., Ishii, Y., Iwanaga, M., Nurrochmad, A., Ito, Y., Mackenzie, P. I., Nagata, K., Yamazoe, Y., Oguri, K., Yamada, H. (2009). Interaction of cytochrome P450 3A4 and UDP-glucuronosyltransferase 2B7: evidence for protein-protein association and possible involvement of CYP3A4 J-helix in the interaction. *Mol Pharmacol* 75:956-964.
- 275 Toriyabe, T., Nagata, K., Takada, T., Aratsu, Y., Matsubara, T., Yoshinari, K., Yamazoe, Y. (2009). Unveiling a new essential cis-element for the transactivation of the CYP3A4 gene by xenobiotics. *Mol Pharmacol* 75:677-684.
- 276 Matsuoka-Kawano, K., Yoshinari, K., Nagayama, S., Yamazoe, Y. (2010). TSU-16, (Z)-3-[(2,4-dimethylpyrrol-5-yl)methylidene]-2-indolinone, is a potent activator of aryl hydrocarbon receptor and increases CYP1A1 and CYP1A2 expression in human hepatocytes. *Chem Biol Interact* 185:33-41.
- 277 Miyata, M., Nomoto, M., Sotodate, F., Mizuki, T., Hori, W., Nagayasu, M., Yokokawa, S., Ninomiya, S., Yamazoe, Y. (2010). Possible protective role of pregnenolone-16 α -carbonitrile in lithocholic acid-induced hepatotoxicity

- through enhanced hepatic lipogenesis. *Eur J Pharmacol* 636:145-154.
- 278 Sato, W., Suzuki, H., Sasaki, T., Kumagai, T., Sakaguchi, S., Mizugaki, M., Miyairi, S., Yamazoe, Y., Nagata, K. (2010). Construction of a system that simultaneously evaluates CYP1A1 and CYP1A2 induction in a stable human-derived cell line using a dual reporter plasmid. *Drug Metab Pharmacokinet* 25:180-189.
- 279 Yoshinari, K., Yoda, N., Toriyabe, T., Yamazoe, Y. (2010). Constitutive androstane receptor transcriptionally activates human CYP1A1 and CYP1A2 genes through a common regulatory element in the 5'-flanking region. *Biochem Pharmacol* 79:261-269.
- 280 Inoue, S., Yoshinari, K., Sugawara, M., Yamazoe, Y. (2011). Activated sterol regulatory element-binding protein-2 suppresses hepatocyte nuclear factor-4-mediated Cyp3a11 expression in mouse liver. *Mol Pharmacol* 79:148-156.
- 281 Koyama, N., Yamazoe, Y. (2011). Development of two-dimensional template system for the prediction of CYP2B6-mediated reaction sites. *Drug Metab Pharmacokinet* 26:309-330.
- 282 Kumagai, T., Suzuki, H., Sasaki, T., Sakaguchi, S., Miyairi, S., Yamazoe, Y., Nagata, K. (2011). Polycyclic aromatic hydrocarbons activate CYP3A4 gene transcription through human pregnane X receptor. *Drug Metab Pharmacokinet* 27:200-206.
- 283 Matsuda, T., Shimada, M., Sato, A., Akase, T., Yoshinari, K., Nagata, K., Yamazoe, Y. (2011). Tumor Necrosis Factor-Alpha–Nuclear Factor-Kappa B-Signaling Enhances St2b2 Expression during 12-O-Tetradecanoylphorbol-13-acetate-Induced Epidermal Hyperplasia. *Biol Pharm Bull* 34:183-190.
- 284 Miyata, M., Sakaida, Y., Matsuzawa, H., Yoshinari, K., Yamazoe, Y. (2011a). Fibroblast growth factor 19 treatment ameliorates disruption of hepatic lipid metabolism in farnesoid x receptor (fxr)-null mice. *Biol Pharm Bull* 34:1885-1889.
- 285 Miyata, M., Yamakawa, H., Hamatsu, M., Kuribayashi, H., Takamatsu, Y., Yamazoe, Y. (2011b). Enterobacteria modulate intestinal bile acid transport and homeostasis through apical sodium-dependent bile acid transporter

- (SLC10A2) expression. *J Pharmacol Exp Ther* 336:188-196.
- 286 Yamaura, Y., Yoshinari, K., Yamazoe, Y. (2011). Predicting oxidation sites with order of occurrence among multiple sites for CYP4A-mediated reactions. *Drug Metab Pharmacokinet* 26:351-363.
- 287 Yamazoe, Y., Ito, K., Yoshinari, K. (2011). Construction of a CYP2E1-template system for prediction of the metabolism on both site and preference order. *Drug Metab Rev* 43:409-439.
- 288 Yoshinari, K., Sakamoto, M., Senggunprai, L., Yamazoe, Y. (2011). Clioquinol is sulfated by human jejunum cytosol and SULT1A3, a human-specific dopamine sulfotransferase. *Toxicol Lett* 206:229-233.
- 289 Arakawa, S., Maejima, T., Fujimoto, K., Yamaguchi, T., Yagi, M., Sugiura, T., Atsumi, R., Yamazoe, Y. (2012). Resistance to acetaminophen-induced hepatotoxicity in glutathione S-transferase Mu 1-null mice. *J Toxicol Sci* 37:595-605.
- 290 Araki, K., Watanabe, K., Yamazoe, Y., Yoshinari, K. (2012a). Liver X receptor alpha bidirectionally transactivates human CYP1A1 and CYP1A2 through two cis-elements common to both genes. *Toxicol Lett* 215:16-24.
- 291 Araki, N., Tsuruoka, S., Hasegawa, G., Yanagihara, H., Omasa, T., Enosawa, S., Yamazoe, Y., Fujimura, A. (2012b). Inhibition of CYP3A4 by 6',7'-dihydroxybergamottin in human CYP3A4 over-expressed hepG2 cells. *J Pharm Pharmacol* 64:1715-1721.
- 292 Benoki, S., Yoshinari, K., Chikada, T., Imai, J., Yamazoe, Y. (2012). Transactivation of ABCG2 through a novel cis-element in the distal promoter by constitutive androstane receptor but not pregnane X receptor in human hepatocytes. *Arch Biochem Biophys* 517:123-130.
- 293 Kumagai, T., Suzuki, H., Sasaki, T., Sakaguchi, S., Miyairi, S., Yamazoe, Y., Nagata, K. (2012). Polycyclic aromatic hydrocarbons activate CYP3A4 gene transcription through human pregnane X receptor. *Drug Metab Pharmacokinet* 27:200-206.
- 294 Kuribayashi, H., Miyata, M., Yamakawa, H., Yoshinari, K., Yamazoe, Y. (2012). Enterobacteria-mediated deconjugation of taurocholic acid enhances ileal farnesoid X receptor signaling. *Eur J Pharmacol* 15:132-138.
- 295 Matsunaga, T., Maruyama, M., Matsubara, T., Nagata, K., Yamazoe, Y.,

- Ohmori, S. (2012). Mechanisms of CYP3A Induction by glucocorticoids in human fetal liver cells. *Drug Metab Pharmacokinet* 25:653-657.
- 296 Miyata, M., Hata, T., Yamakawa, H., Kagawa, T., Yoshinari, K., Yamazoe, Y. (2012). Involvement of multiple elements in FXR-mediated transcriptional activation of FGF19. *J Steroid Biochem Mol Biol* 132:41-47.
- 297 Sato, K., Yamazoe, Y. (2012). Unimolecular and bimolecular binding system for the prediction of CYP2D6-mediated metabolism. *Drug Metab Dispos* 40:486-496.
- 298 Yamada, T., Tanaka, Y., Hasegawa, R., Sakuratani, Y., Yamada, J., Kamata, E., Ono, A., Hirose, A., Yamazoe, Y., Mekenyan, O., Hayashi, M. (2012a). A category approach to predicting the repeated-dose hepatotoxicity of allyl esters. *Regul Toxicol Pharmacol* 65:189-195.
- 299 Yamada, T., Tanaka, Y., Zhang, H., Hasegawa, R., Sakuratani, Y., Mekenyan, O., Yamazoe, Y., Yamada, J., Hayashi, M. (2012b). A category approach to predicting the hemolytic effects of ethylene glycol alkyl ethers in repeated-dose toxicity. *J Toxicol Sci* 37:503-515.
- 300 Yoshinari, K., Ohno, H., Benoki, S., Yamazoe, Y. (2012). Constitutive androstane receptor transactivates the hepatic expression of mouse Dhcr24 and human DHCR24 encoding a cholesterologenic enzyme 24-dehydrocholesterol reductase. *Toxicol Lett* 208:185-191.
- 301 Yamada, T., Hasegawa, R., Nishikawa, S., Sakuratani, Y., Yamada, J., Yamashita, T., Yoshinari, K., Yamazoe, Y., Kamata, E., Ono, A., Hirose, A., Hayashi, M. (2013). A new parameter that supports speculation on the possible mechanism of hypothyroidism induced by chemical substances in repeated-dose toxicity studies. *J Toxicol Sci* 38:291-299.
- 302 Imai, J., Yamazoe, Y., Yoshinari, K. (2013). Novel cell-based reporter assay system using epitope-tagged protein for the identification of agonistic ligands of constitutive androstane receptor (CAR). *Drug Metab Pharmacokinet* 25.
- 303 Ohbuchi, M., Yoshinari, K., Kaneko, H., Matsumoto, S., Inoue, A., Kawamura, A., Usui, T., Yamazoe, Y. (2013). Coordinated roles of pregnane X receptor and constitutive androstane receptor in auto-induction of voriconazole metabolism in mice. *Antimicrob Agents Chemother* 28.

(2) 和文

- 1 山添康, 加藤隆一. (1978). 医学分野における GC/MS の利用と問題点. 慶応医学 55:387-397.
- 2 加藤隆一, 山添康. (1980). 癌原性物質の代謝的活性化の系統差、種差. 変異原と毒性 3:71-88.
- 3 加藤隆一, 山添康. (1981a). 薬理遺伝学とは. 月刊薬事 23:1039-1046.
- 4 加藤隆一, 山添康. 1981b. 病態動物の利用とその問題点. In: 日本アイソトープ協会, 編. ラジオアイソトープ 薬物代謝実験法: 丸善. p 265-275.
- 5 山添康, 石井賢二, 三田四郎. (1981). アミノ酸あるいは蛋白加熱分解生成物の代謝的活性化と毒性発現. 変異原と毒性 4:53-71.
- 6 山添康, 鎌滝哲也. (1981). 化学物質の代謝的活性化と毒性発現の性差、系統差、種差. 変異原と毒性 4:72-88.
- 7 石井賢二, 山添康, 加藤隆一. (1981). Ames 試験の変法. 変異原と毒性 4:72-77.
- 8 山添康. (1982). 肝における薬物代謝酵素の誘導と阻害. 変異原と毒性 5:408-435.
- 9 加藤隆一, 山添康, 鎌滝哲也. (1983). 加熱食品中変異原 IQ の代謝的活性化. 環境変異原研究 5:29-31.
- 10 山添康. 1983a. 医薬品や化学物質の代謝の系統差とチトクローム P-450. In: 加藤隆一, 鎌滝哲也, 編. 薬物代謝の比較生化学: 清至書院. p 69-82.
- 11 山添康. 1983b. アセチル転移酵素とアリルヒドロキサム酸 N,O-アシル転移酵素の性差、系統差、種差. In: 加藤隆一, 鎌滝哲也, 編. 薬物代謝の比較生化学: 清至書院. p 508-522.
- 12 山添康. 1983c. 硫酸転移酵素の性差、系統差、種差. In: 加藤隆一, 鎌滝哲也, 編. 薬物代謝の比較生化学: 清至書院. p 523-534.
- 13 加藤隆一, 山添康. (1986). 癌原物質とその作用機序. 日本臨床 44:281-288.
- 14 加藤隆一, 山添康. (1987). 薬物の立体異性と立体選択的代謝. トキシコロジーフォーラム 10:247-263.
- 15 山添康. (1987). 化学物質による膀胱癌の誘発とその代謝活性化機構. 慶応医学 64:697-700.
- 16 山添康, 加藤隆一. 1987. 薬物代謝. In: 岡博, 三輪剛, 出月康夫, 大藤正雄, 戸

- 田剛太郎, 編. Annual Review 消化器 1987: 中外医学社. p 142-150.
- 17 加藤隆一, 山添康. 1988. 代謝による化学物質の活性化. In: 佐藤了, 大村恒雄, 編. 薬物代謝の酵素系 講談社サイエンティフィック. p 195-233.
- 18 加藤隆一, 山添康, 山本慧. 1988. 発がんの生化学機構. In: 鹿取信, 室田誠逸, 山本尚三, 編. 炎症・アレルギー・免疫・がん: 東京化学同人. p 319-330.
- 19 山添康, 加藤隆一. (1988). 脳下垂体ホルモンによる肝 P-450 酵素の調節. 医学のあゆみ 146:736.
- 20 加藤隆一, 山添康. (1989a). 鎮痛・抗炎症薬の薬理遺伝学. 臨床医学 15:1620-1624.
- 21 加藤隆一, 山添康. (1989b). 肝臓と薬物の相互関係. 肝胆膵 19:731-732.
- 22 山添康. (1989). 環境変異原の酵素的活性化機構の研究. 環境変異原研究 11:81-85.
- 23 山添康, 加藤隆一. 1989a. 共有結合. In: 佐藤哲男, 上野芳夫, 遠藤仁, 編. 生化学的試験法の実際: 地人書館. p 159-162.
- 24 山添康, 加藤隆一. 1989b. アセチルトランスフェラーゼ. In: 佐藤哲男, 上野芳夫, 遠藤仁, 編. 薬物代謝: 地人書館. p 268-272.
- 25 山添康, 安盛俊雄, 加藤隆一. (1989a). 毒性評価における種特異性の問題点、5. 薬物動態の面から見た種特異性. J. Toxicol. Sci. 14S:50-55.
- 26 山添康, 小沢正吾, 加藤隆一. 1989b. フリーラジカル. In: 佐藤哲男, 上野芳夫, 遠藤仁, 編. 生化学的試験法の実際: 地人書館. p 154-158.
- 27 加藤隆一, 山添康. 1990a. 肝における薬物代謝 -第1相薬物代謝-. In: 星猛, 入来正己, 木谷健一, 戸田剛太郎, 編. 肝臓: 南江堂. p 126-134.
- 28 加藤隆一, 山添康. 1990b. 代謝化学. In: 林裕造, 大沢仲昭, 編. 安全性評価の基礎と実際: 地人書館. p 73-89.
- 29 山添康. (1990). 抱合反応による活性化と不活性化. 環境変異原研究 12:283-289.
- 30 山添康. 1990 肝酵素と疾病. In 疾病の発現 - 肝研究の糸口 第8回関東肝臓集談会 編. ライフサイエンス出版. P51-64.
- 31 山添康. 1991. 代謝活性化の経路 代謝活性化と変異活性. In: 石館基, 祖父尼俊雄, 編. 医薬品の変異原性・遺伝毒性: 廣川書店. p 303-317.
- 32 安盛俊雄, 山添康. 1992. 異種細胞における薬物代謝酵素の発現. In: 日本生化学会, 編. 新生化学実験講座 5 生体酸化・薬物代謝: 東京化学同人. p 413-422.
- 33 山添康. 1992. アセチルトランスフェラーゼ. In: 日本生化学会, 編. 新生化学

- 実験講座 5 生体酸化・薬物代謝: 東京化学同人. p 350-360.
- 34 小沢正吾, 永田清, 山添康, 加藤隆一. (1993). アリル(フェノール)硫酸転移酵素分子種の多様性. 薬物動態 8:673-676.
- 35 山添康, 加藤隆一. 1993. 薬物代謝酵素を解き明かす-シトクロム P450 による対掌体識別. モレキュラー・キラリティー 化学同人. p 147-154.
- 36 山添康, 永田清. (1993). ヒトにおける薬物代謝の遺伝的多型. 日薬理学会誌 101:69-77.
- 37 山添康, 永田清, 小沢正吾. (1993). スルホトランスフェラーゼの構造に関する研究の最近の進歩. 薬物動態 8:1147-1154.
- 38 山添康, 安盛俊雄, 永田清, Yang, S. K., 加藤隆一. (1994). ジアゼパムの代謝に関与するチトクローム P450 のヒトとラットの比較. 臨床薬理 25:161-162.
- 39 山添康, 村山典恵. (1994). 薬物代謝と内分泌. 薬局 45:375-381.
- 40 山添康. (1995a). ヒト P450 の発現とその利用の分子生物学的問題点. 薬物動態 10:386-390.
- 41 山添康. 1995b. 薬物の抱合反応に関与する酵素系. In: 加藤隆一, 鎌滝哲也, 編. 薬物代謝学. 1 ed: 東京化学同人. p 74-85.
- 42 山添康. 1995c. 肝薬物代謝酵素の内分泌による制御機構. 薬学研究奨励財団研究成果報告: 薬学研究奨励財団. p 155-162.
- 43 山添康, 出川雅邦. 1995. 発がん抑制剤における薬物代謝の意義. In: 加藤隆一, 鎌滝哲也, 編. 薬物代謝学. 2 ed: 東京化学同人. p 199-210.
- 44 山添康. 1996. 発がん性 In: 佐藤哲男, 仮家公夫, 北田光一, 編. 医薬品トキシコロジー: 南江堂. p 121-126.
- 45 山添康, 出川雅邦. 1996. 変異原性. In: 佐藤哲男, 仮家公夫, 北田光一, 編. 医薬品トキシコロジー: 南江堂. p 127-133.
- 46 山添康. (1997a). ヒトにおける代謝予測と立体選択的代謝. J Mass Spectrom Soc Jpn 45:237-245.
- 47 山添康. (1997b). ヒト P450 の活性部位構造と立体選択性. 臨床薬理の進歩:1-10.
- 48 石神未知, 山添康. (1998). チトクローム P450 が関与する HMG-CoA 還元酵素阻害剤の薬物相互作用. Prog Med 18:972-980.
- 49 山添康. (1999). グレープフルーツジュースとの相互作用. 薬局 50:2171-2179.
- 50 山添康, 島田美樹. (1999). ファルマコジェネティクス/ファルマコゲノミクス研究の現状. ヒューマンサイエンス 10:24-29.

- 51 山添康, 永田清. 1999. 薬物相互作用. In: 加藤隆一, 水島裕, 編. 岩波講座 現代医学の基礎 13 薬物動態と薬効: 岩波書店. p 77-96.
- 52 山添康. (1999). グレープフルーツジュースと薬物相互作用. 日薬理誌: 113-280
- 53 山添康. 2000a. グレープフルーツジュース薬物相互作用. 臨床薬理の進歩 2000. 68-77 p.
- 54 山添康. (2000b). 薬物代謝に及ぼす飲酒, 食事などの影響. 臍胆肝 40:825-831.
- 55 山添康. (2000c). 高脂血症治療薬の注意すべき副作用・留意すべき相互作用. 薬局 51:1857-1862.
- 56 山添康, 永田清. (2000a). 食品や dietary supplements との薬物相互作用. 医学のあゆみ 195:268.
- 57 山添康. 2000d. 発がん抑制における薬物代謝の意義. In: 加藤隆一, 鎌滝哲也, 編. 薬物代謝学 医療薬学・毒性学の基礎として. 2 ed: 東京化学同人. p 213-224.
- 58 山添康. 2000e. 薬物の抱合反応に関与する酵素系. In: 加藤隆一, 鎌滝哲也, 編. 薬物代謝学 医療薬学・毒性学の基礎として. 2 ed: 東京化学同人. p 41-52.
- 59 山添康. (2000f). 薬物代謝からみた薬物相互作用. BIO Clinica 15:55-60.
- 60 山添康, 永田清. (2000c). 物理化学的視点からみた薬物の代謝. 月刊薬事 42:2413-2417.
- 61 荻野淳, 永田清, 山添康. (2000). 薬物による CYP3A 誘導の分子機序とその種差. 薬物動態 15:52-56.
- 62 山添康. 2001. 異物の体内動態と代謝 In: 井上圭三, 小栗一太, 山添康, 編. 衛生薬学新論: 南山堂. p 403-412.
- 63 山添康, 宮田昌明. 2001. 化学物質の毒性と試験法. In: 井上圭三, 小栗一太, 山添康, 編. 衛生薬学新論: 南山堂. p 431-442.
- 64 山添康, 永田清. (2001). 薬物代謝酵素の遺伝多型の研究現状-Cytochrome P450 を中心に. 日本臨牀 59:1614-1623.
- 65 島田美樹, 山添康. (2001). ヒト抱合酵素の遺伝子多型と薬物代謝の個人差. 遺伝子医学 5:22-26.
- 66 永田清, 荻野淳, 山崎亭, 大久保貴之, 高田智成, 古川正幸, 山添康. (2001). ヒト CYP3A4 誘導の分子機構. 薬物動態 16:485-490.
- 67 福田勝行, 郭聯慶, 山添康. (2001). グレープフルーツジュース中のチトクロム P450 代謝阻害物質. 薬局 52:35-46.

- 68 山添康, 郭聯慶. (2001). グレープフルーツジュース相互作用の特徴と個人差. 臨床医 27:727-729.
- 69 永田清, 山添康. (2001). 薬物代謝酵素研究の進歩. 谷本学校 毒性質問箱 4:17-27.
- 70 山添康. (2002a). 薬効・動態における男女差 女性に副作用が多く起こるのはなぜか. 医薬ジャーナル 38:1479-1483.
- 71 山添康. 2002b. 代謝反応. In: 日本トキシコロジー学会教育委員会, 編. トキシコロジー: 朝倉書店. p 47-64.
- 72 山添康, 永田清. (2002). P450 などの薬物代謝酵素にみられるポリモルフィズムと今後の薬物処方. Drug Delivery System 17:103-112.
- 73 島田美樹, 山添康. (2002). 薬効・動態における男女差. 日本薬剤師会雑誌 54:1751-1757.
- 74 平塚真弘, 水柿道直, 山添康. (2002). N-アセチル化転移酵素の多型と薬効. 臨床検査 46:72-76.
- 75 加藤隆一, 杉山雄一, 山添康, 東純一. (2003). 薬物相互作用の今日の考え方～CYPによる薬物の代謝を軸に～. 診療と新薬 40:3-13.
- 76 山添康. 2003a. 癌原性物質の活性化. In: 大村恒雄, 石村巽, 藤井義明, 編. P450の分子生物学: 講談社サイエンティフィック. p 157-167.
- 77 山添康. (2003b). ファーマコゲノミクス. 臨床化学 32:53-54.
- 78 山添康. 2003c. 創薬から臨床へ. In: 佐藤哲男, 堀井邦雄, 山添康, 編. 薬物動態研究ガイド: エル・アイ・シー. p 273-285.
- 79 宮田昌明, 高野泰樹, 山添康. (2004). 発がん物質による標的臓器のDNA損傷におけるグレープフルーツジュース飲用の影響 食物成分の相互作用. Environ Mutagen Res 26:247-251.
- 80 松原勤, 永田清, 山添康. 2005. 小腸 肝以外のヒト組織を用いた動態研究. In: 大野泰雄, 上川雄一郎, 杉山雄一, 山添康, 編. 摘出ヒト組織・細胞を用いた非臨床研究: エル・アイ・シー. p 294-296.
- 81 永田清, 金恵枝, 山添康. 2005. 代謝酵素の発現系. In: 大野泰雄, 上川雄一郎, 杉山雄一, 山添康, 編. 摘出ヒト組織・細胞を用いた非臨床研究: エル・アイ・シー. p 351-354.
- 82 山添康. (2007). 【薬物クリアランス(代謝、取り込み、排泄)および組織移行特性の予測】～代謝特性、クリアランス、相互作用の予測 薬物代謝酵素代謝モデル. 遺伝子医学MOOK 2:84-89.

- 83 吉成浩一, 降幡知巳, 千葉寛, 山添康. 2008. トランスポーターの発現調節機構. In: 杉山雄一, 楠原洋, 編. 分子薬物動態学: 南山堂. p 628-640.
- 84 小林カオル, 吉成浩一, 山添康, 千葉寛. 2008. 酵素の誘導機構. In: 杉山雄一, 楠原洋, 編. 分子薬物動態学: 南山堂. p 612-624
- 85 小澤正吾, 山添康. 2009. 代謝反応. 新版トキシコロジー: 日本トキシコロジー学会教育委員会. p 29-46.
- 86 上野光一, 山添康, 小澤正吾. 2009. 排泄. 新版トキシコロジー: 日本トキシコロジー学会教育委員会. p 47-50.
- 87 山添康, 吉成浩一. 2009. 発癌性化学物質や薬物の代謝的活性化. In: 大村恒雄, 石村巽, 藤井義明, 編. P450 の分子生物学 第2版: 講談社サイエンティフィク. p 184-194.
- 88 山添康. 2010a. 発がん抑制剤における薬物代謝の意義. In: 加藤隆一, 山添康, 横井毅, 編. 薬物代謝学 医療薬学・医薬品開発の基礎として: 東京化学同人. p 202-212.
- 89 山添康. 2010b. 薬物の抱合反応に関与する酵素系. In: 加藤隆一, 山添康, 横井毅, 編. 薬物代謝学 医療薬学・医薬品開発の基礎として: 東京化学同人.
- 90 山添康. 2010c. 発がん物質. 医薬品トキシコロジー 医薬品を安全に使うために 改訂第4版. p 128-133.
- 91 山添康, 小栗一太. 2010. 薬物の代謝反応. 薬物代謝学 医療薬学・医薬品開発の基礎として: 東京化学同人. p 11-42.
- 92 山添康. 2012. 代謝/動態研究と食の安全性及び有効性の評価. 第19回食と健康: 食生活研究会. p 9-34.

III 解説 (紹介)

- 1 加藤隆一, 山添康. (1986a). 細胞死の生化学 医学のあゆみ 137:593-596.
- 2 加藤隆一, 山添康. (1986b). 薬物・ステロイドホルモン代謝の性差発現機序. 医学のあゆみ 141:904-906.
- 3 山添康, 加藤隆一. (1988). 脳下垂体ホルモンによる肝 P-450 酵素の調節. 医学のあゆみ 146:736.
- 4 山添康, 永田清. (1989a): TINABA 博士の講演 Drug metabolizing enzyme deficiencies-Pharmacogenetic comparison between Japanese and other ethnic groups を聞いて. 月刊薬事 31:373-375.

- 5 山添康, 永田清. (1989b). 合成医薬品にみる光学異性体とその作用. *ファルマシア* 25:333-336.
- 6 平山千里, 山添康, 浪久利彦, 奥平雅彦. (1989). 座談会 肝臓と薬物. *肝胆膵* 19:819-827.
- 7 山添康. (1994). 薬物の立体選択的代謝とチトクローム P450. *ファルマシア* 30:1289-1294 (1240-1245).
- 8 橋田 充, 山添 康, 大野泰雄, 佐々木康綱 杉山雄一 (1996) 医薬品開発における薬物体内動態試験の役割. *薬事日報*, 8654(H.8.4.8), 3-8
- 9 永田清, 山添康. (1997). ヒト P450 分子種の *in vitro* 同定法と問題点. *医学のあゆみ* 182:807-811.
- 10 野津克忠, 増保安彦, 八木田秀雄, 山添康, 豊島聡. (1997). ヒト化技術と医薬品の開発. *ファルマシア* 33:13-18.
- 11 島田美樹, 山添康. (1999). ヒト薬物代謝酵素の遺伝的多型 フェノタイプからゲノタイプへ. *ファルマシア* 35:797-801.
- 12 山添康, 永田清. (2000). 食品や dietary supplements との薬物相互作用. *医学のあゆみ* 195:268.
- 13 Eichelbaum, M., Evans, W. E., Yamazoe, Y. (2002). From the Editors: progress and the way forward. *Pharmacogenetics* 12:273-274.
- 14 山添康. (2007). くすりの安全への取り組みについて思うこと. *ファルマシア* 43:1049.
- 15 Yamazoe, Y. (2008). Our recent activities on communication with overseas. *Drug Metab Pharmacokinet* 23:393.
- 16 山添康. (2010). 我が国におけるヒト組織を用いた研究の必要性の理解を得るために. *HAB Newslette* 17:2.
- 17 齊藤直樹, 松田敏夫, 宮田直樹, 森裕志, 山添康, 有賀寛芳. (2011). みんなで育てよう!. *ファルマシア* 47:112.
- 18 山添康. (2013). 食品安全の現状と課題. *ファルマシア* 49:1.

IV 会議・学会発表

- 1 山添康, 福田勝行, 吉川正美, 中村隆弘, 聯慶, 郭., 馬場きみ江, 太田富久. 1997. グレープフルーツジュースと薬物の代謝相互作用. *日本薬物動態学会*; 1997. p. S122-S123.

- 2 Yamazoe, Y., Kitada, H., Nakamura, T., Tozawa, A., Honma, W., Shimada, M., Nagata, K., Christopher, J. 2002. Protective role of hydroxysteroid sulfotransferase in lithocholic acid-induced liver toxicity. 中日毒理学・薬理学総合検討会 shenzhen p 406.
- 3 山添康. 2006. 薬物代謝の個人差と薬物相互作用 ―薬物使用の最適化に向けて―. 湯雄医報. p 10-11.